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 ABSTRACT 
BACKGROUND: 
The supplementation of local anaesthetics with adjuvants to improve the 
efficacy of subarachnoid block has been recognised since long. The most 
preferred drug has been opioids, but newer drugs like dexmedetomidine has also 
been introduced and investigated as an effective adjuvant. 
AIM: 
This study was conducted to evaluate and compare the characteristics of 
subarachnoid blockade, hemodynamic stability and adverse effects of 
intrathecal buprenorphine and intrathecal dexmedetomidine as an adjuvant to 
0.5% hyperbaric bupivacaine for lower abdominal surgeries. 
MATERIALS AND METHODS: 
The present study included 60 patients aged between 18-60 years classified as 
American Society of Anaesthesiologists (ASA) Physical Status (PS) I/II 
scheduled for elective lower abdominal surgeries. The patients were randomly 
allotted into two groups namely Group BB and Group BD of 30 each. Patients 
in Group BB received 75µg of buprenorphine with 0.5% bupivacaine 15 mg 
intrathecally.Patients in Group BD received 5µg of dexmedetomidine with 0.5% 
bupivacaine 15 mg intrathecally. The onset time to peak sensory level, motor 
block, sedation, Haemodynamic variables, duration of motor block, analgesia 
and any adverse effects were noted. 
RESULT 
There was no significant difference between groups regarding demographic 
characteristics and type of surgery. The motor, sensory blockade and time of 
rescue analgesia were significantly prolonged in Group BD compared to 
GroupBB. The sedation level was higher in Group BD compared to GroupBB. 
There was no significant difference in haemodynamic variables although 
GroupBB had lower Heart Rate (HR) than Group BD. 
CONCLUSION: 
Intrathecal dexmedetomidine when compared to intrathecal buprenorphine 
causes prolonged anaesthesia, analgesia with better degree of sedation and 
reduced need of rescue analgesics. 
KEYWORDS: 
Buprenorphine; Lower abdominal surgery; α–2 adrenergic agonist 
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INTRODUCTION   
“It is the duty of the anesthesiologist to study the well being of the 
patient as well as the convenience of the surgeon” 
-Ralph Waters 
The International Association for the study of pain(IASP) defined pain 
as “an unpleasant sensory or emotional experience associated with actual or 
potential tissue damage or described in terms of such damage”[1]. 
Spinal anaesthesia was first performed by August Bier on 16th August 
1898 when he injected 3 ml of 0.5% Cocaine intrathecally. It is a simple 
technique which has many advantages over epidural anaesthesia. In addition, 
correct placement of the needle in the subarachnoid space is confirmed by a 
clearly defined end point (appearance of CSF). 
Spinal anaesthesia with local anaesthetic agents is extensively used for 
lower abdominal surgeries. It provides the excellent pain relief as compared to 
intravenous or epidural route. 
There are many advantages for spinal anaesthesia over general 
anaesthesia which makes it the anaesthesia of choice in current surgical 
practice. Many clinical studies support the fact that Postoperative morbidity 
and mortality may be reduced when neuraxial blockade is used either alone or 
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in combination with general anaesthesia. Since it decreases the stay, it is cost 
effective for both patient and hospital. It is suitable for patients with respiratory 
diseases and helps in preventing intubation related problem like laryngospasm. 
It is also helpful in maintaining the airway patency and reduced blood loss.  
Early return of gastro intestinal function following surgery can be 
considered as an added advantage. Other advantage may be reduced 
hypercoagulable state  associated with surgery, increased tissue blood flow due 
to sympathectomy, decreased splinting which improves oxygenation, enhanced 
peristalsis, and reduced stress response to surgery due to suppression of 
neuroendocrine system [2]. 
Apart from the theoretical risk of infection to the brain, difficulty in 
finding the space in old age and bony abnormalities can pose a challenge to the 
anesthesiologist. The serious complication associated with spinal anaesthesia 
includes bradycardia, hypotension, prolonged motor block and high spinal [3]. It 
is related to the sympatholytic effect of local anaesthetic agents. 
If the level of the block is higher, the sympatholytic effect will be more 
and leads to more serious complications. Though these effects cannot be 
abolished completely, they can be considerably minimized by using either low 
dose or low concentration of local anaesthetics. One of the main disadvantages 
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is the limited duration of block achieved with local anaesthetics. To overcome 
this, various adjuvants have been tried and used successfully. 
This addition of adjuvant has further expanded the advantage of regional 
anaesthesia like 
i) Rapid onset of action 
ii) Reduces the local anaesthetic requirements 
iii) Reduces the risk of local anaesthetic toxicity 
iv) Prolongs  the sensory block 
v) Reduces the duration of motor block 
vi) Improves the analgesic quality 
vii)  Improves the hemodynamic stability 
viii)  Inhibition of tourniquet pain 
ix)  Improved and prolonged duration of postoperative analgesia. 
Opioids are the time honoured drugs which have been used for this 
purpose. Morphine was the first opioid used intrathecally in 1979, followed by 
other opioids [4 5 6]. Buprenorphine is a centrally acting lipid soluble analogue of 
alkaloid thebaine. It exhibits analgesic property both at spinal and supraspinal 
     
4 
 
levels [7]. It has been used for various surgeries at different doses for the past 
few decades. It has consistently proven to prolong the duration of anaesthesia[8 
9 10]
 . At higher doses, it causes pruritus, drowsiness, nausea and vomiting [11]. 
Dexmedetomidine is a specific α-2 adrenergic agonist[12]. It has been 
extensively used as premedicant, for sedation in the Intensive Care Unit and for 
awake fibreoptic intubation [12 13]. It was first used intrathecally in humans for 
transurethral resection of prostate [14].  It prolongs both sensory and motor 
block and has nociceptive action for both visceral and somatic pain. It is being 
evaluated now as a potential adjuvant to local anaesthetic agents. 
This research is designed to study the efficacy of such combination in 
our setup and compare the results with the previous studies done at other 
institutions. 
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AIM OF THE STUDY 
 
 
To evaluate and compare the following factors in two groups – 
intrathecal dexmedetomidine and intrathecal buprenorphine as an adjuvant to 
0.5% hyperbaric bupivacaine for lower abdominal surgeries, with respect to: 
1. Sensory and motor blockade – Onset and duration. 
2. Haemodynamic changes 
3. Adverse effects  
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ANATOMY 
Spinal anaesthesia results in sympathetic blockade, sensory analgesia or 
anaesthesia and motor blockade. It depends on the dose, concentration or 
volume of local anaesthetic injected into the subarachnoid space. 
  The vertebral canal extends from the foramen magnum to the sacral hiatus. 
There are seven cervical, twelve thoracic and five lumbar vertebrae.  The 
sacrum comprises five and the coccyx four fused segments.  The adult  spine  
presents  four  curvatures:  those  of  the  cervical  and  lumbar zones  are  
convex  forwards (lordosis), whereas those  of  the  thoracic  and  sacral 
regions  are  concave forwards  (kyphosis).  
The  former are postural, while the latter are produced by the actual 
configuration of the  bones themselves. The vertebrae are held together by a 
series of overlapping ligaments[15 16] namely 
• Anterior longitudinal ligament  
• Psterior longitudinal ligament  
• Ligamentum flavum 
• Interspinous ligament  
• Supraspinous ligament  
• Intervertebral discs. 
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There are certain common palpable landmarks that may correspond to 
particular level, including the most prominent spinous process which usually 
corresponds to the seventh cervical vertebra. The inferior angle of scapula 
usually corresponds to the seventh thoracic vertebra. Tuffier line, the line 
connecting the two iliac crests almost crosses the vertebral column at the level 
of L4-L5 intervertebral space. 
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The intervertebral canal consists of: 
1. Roots  of  spinal  nerves 
2. Spinal  membrane  with  the  spinal  cord  and  cerebrospinal  fluid 
3. Vessels, fat and areolar tissue. 
The spinal cord is the continuation of medulla oblongata and it ends 
below in conus medullaris from which filum terminale descends vertically 
as cauda equina. The extent of the spinal cord is from the upper border of 
atlas to the lower border of first lumbar vertebra in adults. The spinal cord 
extends till the upper border of second lumbar vertebra and still lower in 
infants. 
The coverings of spinal cord from outside to inside are 
• duramater  
• arachnoidmater 
• piamater. 
The duramater is attached to the margins of foramen magnum above and 
ends below at the lower border of the second sacral vertebra. The anterior 
and posterior nerve roots from the spinal cord pierce the investing layer of 
duramater and carry the prolongation (dural cuff) which blends with the 
perineurium of the mixed spinal nerve. 
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The arachnoid mater is a thin transparent sheath closely applied to 
duramater. The subdural space is a potential space which contains only 
small amount of serous fluid to allow the dura and arachnoid to move over 
each other. 
The piamater closely invests the cord and sends delicate septa into its 
substances. From each lateral surface of the piamater, a fibrous band, the 
denticulate ligament projects into the subarachnoid space. Inferiorly the 
piamater ends as a prolongation termed as filum terminale which penetrates 
the distal end of dural sac and is attached to the periostium of coccyx. 
The subarachnoid space is filled with the cerebrospinal fluid and it 
contains the spinal nerve roots and the denticulate ligament. Lumbar 
puncture is routinely done below the second lumbar vertebra to L5-S1 
interspace to avoid damaging the spinal cord which ends at the lower border 
of first lumbar vertebra. 
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Blood supply of spinal cord[17] 
 Blood supply of spinal cord is mainly from three longitudinal 
arterial channels namely 
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• One anterior spinal artery 
• Two posterior spinal arteries 
 The main source of blood supply to the spinal arteries is from the 
vertebral arteries. However it reaches only up to the cervical segment of the 
cord. The spinal arteries also receive blood through radicular arteries that 
reaches the cord along the roots of spinal nerves. These radicular arteries from 
the vertebral, ascending cervical, deep cervical, intercostals, lumbar and sacral 
arteries. 
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Only few of these radicular arteries are larger in size. The arteria radicularis 
magna, or artery of Adamkiewicz, the largest of the radicular arteries and it 
may be responsible for supplying blood to as the lower two-thirds of the spinal 
cord. Its position is variable.  
 
There is no anastamosis between the anterior spinal artery and the 
posterior spinal artery. So the occurrence of thrombosis in any of these arteries 
will cause spinal cord infarction. 
 
 Venous drainage of the spinal cord is mainly through six longitudinal 
venous channels. They are anteromedian and posteromedian venous channels 
which lie in the midline and two paired anterolateral and posterolateral 
channels. These channels join together and form a venous plexus, from here the 
venous blood drains through the radicular vein into segmental veins; the 
vertebral veins in the neck, the azygos veins in the thorax, lumbar veins in the 
abdomen and lateral sacral veins in the pelvis.  
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CEREBROSPINAL FLUID[17] 
 The cerebrospinal fluid is an ultrafiltrate of plasma secreted by choroid 
plexus of third, fourth and lateral ventricles at a rate of 0.3 to 0.5ml/min.  The  
average  volume  ranges  from  120 to 150 ml, of  which  25 ml  is  in  the  
cerebral  subarachnoid  space,  35  ml  in the ventricles  and  about 75  ml  is  in  
the  spinal subarachnoid  space . It is a colourless liquid with slight opalescence 
due to globulin. 
 
Circulation of cerebrospinal fluid 
From the lateral ventricles it enters the 3rd ventricles through the 
interventricular foramina. Then it flows through the cerebral aqueduct and it 
reaches the 4th ventricle. Through the foramen of magendie and luschka in the 
roof of the 4th ventricle it enters the subarachnoid space and circulates over the 
cerebral hemispheres and around the spinal cord. 
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Physical Characteristics of Cerebrospinal Fluid 
Ph      : 7.4 
Specific gravity at body temperature : 1.007 
Specific gravity at 4 degree Celsius : 1.0003 
Density     : 1.0003gm/ml 
Baricity     : 1.000   
Pressure in supine position  : 8 – 12 mm of hg 
Cells      : 3 – 5 / cu.mm 
Proteins     : 20mg / dl 
Glucose     : 45 – 80 mg/dl 
 
Absorption 
 The main site of cerebrospinal fluid absorption is into the venous system 
through the arachnoid villi and arachnoid granulations. These are most 
numerous in superior saggital sinus and its lateral lacunae. Approximately 300-
380 ml of cerebrospinal fluid enters venous circulation each day. 
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It  plays  an  important  role  in  spinal anaesthesia  as  a  media  for  
dispersion  of  the  local  anaesthetic  drug  to the  spinal  nerve. Specific  
gravity  of  the  injected  solution  is  an important  factor  in  determining  the  
spread  of  the  local  anaesthetic drug  in the  subarachnoid  space. 
 
SITE OF ACTION OF LOCAL ANAESTHETIC DRUGS[18] 
Local anaesthetic solution injected into the subarachnoid space mixes 
with the cerebrospinal fluid and comes into contact with the spinal cord and the 
peripheral nerve roots. The nerve roots leaving the spinal canal are readily 
exposed to the local anaesthetic solution as they are not covered with 
epithelium. 
 
Zone of Differential Blockade 
In subarachnoid block, sympathetic fibres are blocked two to six 
segments higher than the sensory fibres. Sympathetic block will be greater 
when more concentrated solutions are used or when adrenaline is added. Motor 
block will be two segments below the sensory block. 
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Nerve fibres are blocked in the following order [17] 
1. Autonomic preganglionic  B fibres 
2. Temperature fibres- Cold fibres first followed by warm fibres 
3. Pinprick fibres 
4. Fibres conveying pain greater than pin prick 
5. Touch fibres 
6. Deep pressure fibres 
7. Somatic motor fibres 
8. Fibres conveying vibratory sense and proprioceptive impulses. 
During recovery, sensations return in the reverse order, but it has been 
suggested that sympathetic activity returns before sensation. 
 
SPREAD OF LOCAL ANAESTHETICS IN SUBARACHNOID SPACE 
The local anaesthetic solution is diluted by CSF and therefore its original 
concentration is less than the actual mass of drug injected. Spread is also 
determined by the baricity of the injected solution. Baricity is a ratio 
comparing the density of a local anaesthetic solution at a specific temperature 
to the density of CSF at the same temperature.  
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A hypobaric solution has a baricity less than 1.0000 or specific gravity 
less than 1.0069 (the mean value of specific gravity). A hyperbaric solution has 
a baricity greater than 1.0000 or specific gravity more than 1.0069. Hypobaric 
and Hyperbaric solutions are prepared from isobaric solutions by the addition 
of various amounts of sterile distilled water and dextrose respectively. 
Isobaric solutions do not move under the influence of gravity in the CSF. 
Hyperbaric solutions, being heavier than CSF, settle to the most dependent 
aspect of the subarachnoid space, which is determined by the position of the 
patient. In supine patient, hyperbaric solutions gravitate to the thoracic 
kyphosis. Hypobaric solution floats up against the gravity to the nerves 
innervating the surgical site.  
 
FATE OF LOCAL ANAESTHETICS IN SUBARACHNOID SPACE 
After injection of local anaesthetic solution into subarachnoid space, its 
concentration falls rapidly. The initial steep fall is due to mixing with CSF and 
subsequent absorption into nerve roots and spinal cord. The removal of local 
anaesthetic solution following subarachnoid injection is primarily by vascular 
absorption. 
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 Depending on the type of the drug used, it is metabolized in plasma by 
pseudo cholinesterase or in the liver.  The addition of a vasoconstrictor to the 
local anaesthetic solution will decrease the absorption of the drug and thus 
increase the duration of anaesthesia. 
 
 
PHYSIOLOGICAL EFFECTS OF SUBARACHNOID BLOCK 
 
Cardiovascular effects 
Vasomotor tone is determined by sympathetic fibers arising from T5 to 
L1 and innervating arterial and venous smooth muscle. Hence sympathetic 
block will cause a decrease in blood pressure that may be accompanied by a 
decrease in heart rate. With high sympathetic block, sympathetic cardiac 
accelerator fibers arising at T1-T4 are blocked, leading to decreased cardiac 
contractility. Bezold-Jarisch reflex has been implicated as a cause of 
bradycardia, hypotension and cardiovascular collapse after central neuraxial 
anaesthesia, in particular spinal anaesthesia. 
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Respiratory effects 
Even with high thoracic levels, the tidal volume remains unchanged. A 
small decrease in vital capacity is due to paralysis of abdominal muscles 
necessary for forced exhalation and not due to phrenic nerve involvement or 
impaired diaphragmatic function. Effective coughing and clearing of secretions 
may get affected with higher levels of block.  Respiratory arrest associated 
with spinal anaesthesia is rare and is due to hypo perfusion of respiratory 
centers in brain stem.   
 
Gastrointestinal function 
  Nausea and vomiting is seen in upto 20% of patients. It is due to 
gastrointestinal hyperperistalsis caused by unopposed parasympathetic activity. 
Vagal tone dominance results in a small contracted gut with active peristalsis 
and can provide excellent operative conditions. Hepatic blood flow will 
decrease with reductions in mean arterial pressure. 
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Renal function 
Renal function has a wide physiological reserve. Decrease in renal blood 
flow is of little physiological importance.  Neuraxial blocks are a frequent 
cause of urinary retention which delays discharge of outpatients and 
necessitates bladder catheterization of inpatients.  
 
 
INDICATIONS FOR SUBARACHNOID BLOCK 
Spinal anaesthesia can be administered for surgeries below umbilicus such 
as  
• Lower abdominal surgeries 
• Lower limb surgeries 
• Urological procedures 
• Obstetric procedures 
• Gynaecological surgeries 
• Perineal and rectal surgeries 
 
 
     
21 
 
CONTRAINDICATIONS FOR SUBARACHNOID BLOCK 
The  absolute  contraindication for subarachnoid block are 
• Patient refusal 
• Local sepsis 
 
The relative contraindications include 
• Raised intracranial pressure 
• Coagulopathy 
• Neurological disease 
• Fixed cardiac output states 
• Documented allergy to local anaesthetics 
• Major spine deformities or previous surgery on the spine 
• Hemodynamic instability 
 
FACTORS INFLUENCING HEIGHT OF ANALGESIA IN  
SUBARACHNOID BLOCK 
• Dose of the drug injected 
• Volume of fluid injected 
• Specific gravity of the solution 
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• Position of the patient during injection 
• Posture of patient after injection 
• Choice of interspace 
• Patient factors- Age, Height and Pregnancy 
 
FACTORS NOT INFLUENCING HEIGHT OF ANALGESIA IN  
SUBARACHNOID BLOCK 
• Patient factors- Weight, Sex. 
• Barbotage. 
• Rate of injection. 
• Composition and circulation of cerebrospinal fluid. 
• Direction of bevel of the standard needle (although not of the Whitacare 
needle). 
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COMPLICATIONS OF SUBARACHNOID BLOCK 
The Immediate complications include 
• Hypotension 
• Bradycardia 
• Toxicity due to intravascular injection 
• Allergic reaction to local Anaesthetic 
• Hypoventilation ( brain stem hypoxia ) 
 
The late complications include 
• Postdural puncture headache 
• Retention of urine 
• Backache 
• Meningitis 
• Transient neurological symptoms 
• Cauda equine syndrome 
• Anterior spinal artery syndrome 
• Horner’s  syndrome 
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LOCAL ANAESTHETIC DRUGS 
 Local anaesthetic agents are divided into two groups namely the amides 
and esters 
Esters 
• Benzocaine 
• Chloroprocaine 
• Cocaine 
• Cyclomethycaine 
• Dimethocaine 
• Piperocaine 
• Propoxycaine 
• Procaine 
• Proparacaine 
• Tetracaine/Amethocaine 
 
Amides 
• Articaine 
• Bupivacaine 
• Dibucaine 
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• Etidocaine 
• Levobupivacaine 
• Lignocaine 
• Mepivacaine 
• Prilocaine 
• Ropivacaine 
• Trimecain 
 
Adjuvants used in spinal anaesthesia 
Opioids 
• Morphine 
• Fentanyl 
• Sufentanyl 
• Diamorphine 
Clonidine  
Ketamine 
Neostigmine 
Adrenaline  
Phenylepherine 
Sodium bicarbonate 
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PHARMACOLOGY OF BUPIVACAINE[19 20 21] 
Bupivacaine, an amino amide local anaesthetic was first synthesized in 
Sweden by A.F Ekenstam  and his colleagues in 1957. First report of its use 
was in 1963 by L.J Teluvio. It is one of the long acting local anaesthetic agents 
available, which is extensively used for intrathecal, extradural and peripheral 
nerve blocks. It is a white crystalline powder soluble in water 
  
 
CHEMICAL STRUCTURE OF BUPIVACAINE 
Bupivacaine has an IUPAC nomenclature of 1-butyl-n-(2,6- 
dimethylphenyl) piperidine-2-carboxamide. 
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Physiochemical properties[22] 
Molecular formula   : C18 H28 N2O HCl 
Molecular weight   : 288.43 g/mol 
Protein binding          : 95% 
pH of saturated solution  : 5.2 
pKa     : 8.1 
Specific gravity   : 1.021 at 37 °C 
 
 
Mechanism of action[23, 24] 
Mechanism of action of bupivacaine is similar to that of any other local 
anaesthetic. The primary action of local anaesthetics is on the cell membrane 
axon, on which it produces electrical stabilization. Bupivacaine prevents 
transmission of nerve impulses (conduction blockade) by inhibiting passage of 
sodium ions through ion-selective sodium channels in nerve membranes.  
The sodium channel is a specific receptor for local anaesthetic 
molecules. Failure of sodium ion channel permeability to increase slows the 
rate of depolarization such that threshold potential is not reached and thus an 
action potential is not propagated. Local anaesthetics do not alter the resting 
transmembrane potential or threshold potential. 
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The mechanism by which local anaesthetics block sodium conductance 
is as follows 
 
1. Local anaesthetics in the cationic form act on the receptors 
within the sodium channels on cell membrane and block it. The 
local anaesthetics can reach the sodium channel either via the 
lipophilic pathway directly across the lipid membrane, or via 
the axoplasmic opening. This mechanism accounts for 90% of 
the nerve blocking effects of amide local anaesthetics. 
 
2. The second mechanism of action is by membrane expansion. 
This is a nonspecific drug receptor interaction. 
 
Other site of action targets 
• Voltage dependent potassium ion channels 
• Calcium ion currents (L-type most sensitive) 
• G protein coupled receptors 
  
 
 
 
     
29 
 
Dosage depends on 
 Area to be anaesthetized 
 Number of nerve segments to be blocked 
 Individual tolerance 
 Technique of local anaesthesia 
           Vascularity of area 
 
 
AVAILABILITY 
         Ampoules – 0.5% Bupivacaine hydrochloride 4cc 
                 _ 0.5% Bupivacaine with dextrose ( heavy ) 4cc 
        Vials         _ 0.25% and 0.5% Bupivacaine hydrochloride 30 cc 
        Dosage      _ Maximum  dosage  3mg/kg body weight.  
 
 
 ANAESTHETIC POTENCY 
Hydrophobicity appears to be a primary determinant of intrinsic 
anesthetic potency and Bupivacaine is highly hydrophobic, hence is very 
potent. 
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ONSET OF ACTION 
The onset of conduction blockade is dependent on the dose or 
concentration of the local anaesthetic. The onset of action of Bupivacaine is 
between 4 – 6 minutes and maximum anaesthesia is obtained between 15 – 20 
minutes. 
 
 
DURATION OF BLOCK 
The duration of  anaesthesia  varies according to the type of block. The 
average  duration  of   peridural  block is about 3.5 – 5 hours, for nerve block 5 
– 6 hours and for intrathecal block, it is about 1.5 to 2 hours.   
 
 
PHARMACOKINETICS 
 
 The concentration of  Bupivacaine in blood is determined by the amount 
injected, the rate of absorption from the site of injection, the rate of tissue 
distribution and the rate of biotransformation and excretion of Bupivacaine. 
 
Bupivacaine can be detected in the blood within 5 minutes of infiltration 
or following epidural or intercostal nerve blocks. Plasma levels are related to 
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the total dose administered. Peak levels of 0.14 to 1.18 µg/ml were found 
within 5 mins to 2 hrs, and they gradually declined to 0.1 to 0.34 µg/ml by 4 
hrs.  
 
 
Plasma binding  
In plasma, drug binds avidly with protein to the extent of 70 -90%. The 
rank order of protein binding for this and its homologues is bupivacaine, 
mepivacaine, lidocaine. Conversely, the unbound active fraction is one seventh 
of lidocaine and one fifth of mepivacaine. 
  
 
Absorption 
The site of injection, dose and addition of a vasoconstrictor determine 
the systemic absorption of Bupivacaine .The maximum blood level of 
Bupivacaine is related to the total dose of drug administered from any 
particular site. Absorption is faster in areas of high Vascularity. 
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Toxicity 
The toxic plasma concentration is set at 4 - 5 µg/ml. Maximum plasma 
concentration rarely approach toxic levels. 
 
Distribution 
 
Rapid distribution phase: (α) 
          In this phase the drug is distributed to highly vascular region. 
          Half life of α- being 2.7 minutes. 
 
Slow disappearance phase: (β) 
         In this phase the drug distributes to slowly equilibrating tissues. 
         Half life of (β)- being 28 minutes. 
 
Biotransformation and excretion phase: (δ) 
        Half life of δ is 3.5 hours, clearance is 0.47litre/minute.   
More highly perfused organs show higher concentrations of the drug. 
Bupivacaine is rapidly excreted by lung tissue. Though skeletal muscle does 
not show any particular affinity for bupivacaine it is the largest reservoir of the 
drug. 
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Biotransformation and Excretion 
 
Bupivacaine undergoes enzymatic degradation primarily in the liver. The 
excretion occurs primarily via the kidney. Renal perfusion and factors affecting 
urinary pH affect urinary excretion. Less than 5% of Bupivacaine is excreted 
via the kidney unchanged through urine.  
 
The major portion of injected agent appears in urine in the form of 2,6 
pipecolyoxylidine (ppx) which is a n-dealkylated metabolite of bupivacaine. 
Renal clearance of the drug is related inversely to its protein binding capacity 
and pH of urine. 
  
 
PHARMACODYNAMICS 
 
Central Nervous System 
 
Bupivacaine  readily crosses the blood brain barrier causing CNS 
depression following higher doses. The initial symptoms involve feeling of 
light-headedness and dizziness followed by visual and auditory disturbances. 
Disorientation and drowsiness may occur. Objective signs are usually 
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excitatory in nature, which includes shivering, muscular twitches and tremors, 
initially involving muscles of the face (perioral numbness) and part of 
extremities.  
 
At still higher doses cardiovascular or respiratory arrest may occur. 
Acidosis increases the risk of CNS toxicity from Bupivacaine, since an 
elevation of PaCO2 enhances cerebral blood flow, so that more anaesthetic is 
delivered rapidly to the brain 
 
 
Autonomic nervous system 
Bupivacaine does not inhibit the Noradrenaline uptake and hence has no 
sympathetic potentiating effect. Myelinated preganglionic B fibers have a 
faster conduction time and are more sensitive to action of Bupivacaine. When 
used for conduction blockade, all local anaesthetics, particularly Bupivacaine 
produces higher incidence of sensory than motor fibers. 
 
 
Cardiovascular System  
The primary cardiac electrophysiological effect of a local anaesthetic is a 
decrease in the maximum rate of depolarization in Purkinje fibers and 
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ventricular muscle. This action by Bupivacaine is far greater compared to 
Lignocaine. Also, the rate of recovery of block is slower with Bupivacaine.  
 
Therefore there is complete restoration of Vmax between action 
potential particularly at higher rates. Therefore Bupivacaine is highly 
arrythmogenic. Bupivacaine reduces the cardiac contractility by blocking the 
calcium transport. Low concentration of Bupivacaine produces 
vasoconstriction whereas high doses cause vasodilatation. 
 
 
Respiratory System 
 
Respiratory depression may be caused if excessive plasma level is 
reached which in turn results in depression of medullary receptor center. 
Respiratory depression may be also caused by paralysis of respiratory muscles 
of diaphragm as may occur in high spinal or total spinal anaesthesia. 
 
 
Adverse Effects 
Adverse effects are encountered in clinical practice mostly due to 
overdose, inadvertent intravascular injection or slow metabolic degradation. 
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Central nervous system 
It is characterized by excitation or depression. The first manifestation 
may be nervousness, dizziness, blurring of vision or tremors, followed by 
drowsiness, convulsions, unconsciousness and respiratory arrest. 
  
Cardiovascular system 
Myocardial depression, hypotension, arrhythmia, ventricular type 
conduction defect, SA node depression and cardiac arrest 
 
 
Allergic reactions  
Urticaria 
Bronchospasm 
Hypotension 
Others - nausea, vomiting, chills, constriction of pupil  and tinnitus.     
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 TREATMENT OF ADVERSE EFFECTS 
Treatment is mainly symptomatic. One should be prepared to 
maintain circulation and to support ventilation with oxygen or controlled 
ventilation, if required. Supportive treatment with IV fluids and 
vasopressors restore the cardiovascular stability. Convulsions may be 
controlled with Diazepam (0.1- 0.2mg/kg) or Thiopentone (2-3 mg/kg) 
or a muscle relaxant and controlled ventilation with oxygen. 
 
Corticosteroids, if allergic reactions are suspected. Treatment of 
ventricular fibrillation and tachycardia by Amiodarone (5mg/kg iv) or 
defibrillation (2-6 joule/kg).     
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                  PHARMACOLOGY OF DEXMEDETOMIDINE[25 26] 
 
Dexmedetomidine is the d-enantiomer of medetomidine, belongs to the 
imidazole subclass of α2 receptor agonists. It is a more selective α2 agonist with 
a 1600 greater selectivity for the α2 receptor compared with the α1 receptor. It 
was introduced in clinical practice in 1999 and the only FDA approved use of 
dexmedetomidine is for sedation in mechanically ventilated patients in 
intensive care unit. It is now being used off-label outside of the ICU in various 
settings, including sedation and adjunct analgesia in the operating room, 
sedation in diagnostic and procedure units, and for other applications. 
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MECHANISM OF ACTION 
  Alpha2 adrenoreceptors are membrane-spanning G proteins. There are 
three subtypes of α2 adrenergic receptors in humans: α2A, α2B, and α2C.  The α2A 
receptors are distributed mainly in the periphery, likewise α2B and α2C receptors 
are primarily distributed in spinal cord and brain.  
 
Postsynaptic α2 receptors in the peripheral blood vessels produce 
vasoconstriction, whereas α2 receptors located in the presynaptic region inhibit 
the release of norepinephrine, potentially attenuating the vasoconstriction. 
These receptors are involved in the sympatholysis, sedation, and 
antinociceptive effects of α2 receptors. 
 
PHARMACOKINETICS 
 Dexmedetomidine when injected intravenously, it is rapidly distributed 
in the body and it is metabolized mainly in the liver and excreted in urine and 
faeces. Dexmedetomidine is 94% protein bound. The elimination half-life of 
dexmedetomidine is around 2 hours and with a context-sensitive half-time of 4 
minutes to 250 minutes after an 8-hour infusion. Volume of distribution is 118 
litres. Clearance is estimated to be approximately 39litres/ hour. 
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Effects on the central nervous system 
Sedation  
Dexmedetomidine acts on the alpha 2 receptors in locus ceruleus and 
causes sedation as well as hypnosis. It exerts sedative effect by acting  through 
the endogenous sleep-promoting pathways. 
 
Analgesia  
Analgesia produced by dexmedetomidine is complex and not clearly 
known. The spinal cord is thought to be the primary site of action. It causes 
analgesia when injected either in intrathecal or epidural space. 
 
Respiratory System  
When dexmedetomidine is given at doses required to produce significant 
sedation it reduces minute ventilation, but the response to increase in carbon 
dioxide concentration is preserved. Ventilatory changes caused by 
dexmedetomidine is identical to the changes that appear during  normal sleep.  
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Effects on the Cardiovascular System  
Dexmedetomidine causes a decrease in heart rate, myocardial 
contractility, cardiac output, systemic vascular resistance and blood pressure 
myocardial contractility and cardiac output. Dexmedetomidine when given in 
bolus dose has shown a biphasic response. Rapid injection of dexmedetomidine 
in a dose of 2 µg/kg causes a brief rise in the blood pressure (22%) and a 
decrease in the heart rate (27%) from the base line valve.  
This brief rise in blood pressure is due to the stimulation of peripheral 
alpha 2 receptors which causes vasoconstriction. After 15 minutes the heart 
rate came back to the baseline level, and blood pressure gradually declined to 
approximately 15% below baseline by 1 hour. 
 
USES 
Dexmedetomidine is used for sedation in mechanically ventilated 
patients and for procedural sedation prior to or during surgery. 
In operating room, it is used for premedication and a sole anaesthetic 
in monitored anaesthesia care. It is also used as an adjunct with local 
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anaesthetic drugs in peripheral nerve block, intravenous regional 
anaesthesia, epidural and spinal anaesthesia. 
 
Intensive care unit 
 Dexmedetomidine has several advantages over propofol while 
sedating postoperative patients in intensive care units. It reduces opioids 
consumption, PaO2/FIO2 ratio was significantly higher and heart rate was 
slower in dexmedetomidine group. Due to its unique character of providing 
good sedation with less respiratory depression it can be used while weaning 
patients from the ventilator. 
 
Anaesthesia  
 Dexmedetomidine when used as a premedicant it reduces the 
requirements of induction agents, volatile anaesthetics and opioids. It 
suppresses the hemodynamic response to intubation. When used in 
ophthalmic cases it reduces the intraocular pressure and catecholamine 
secretion is reduced. Perioperative analgesic requirements are less, and 
recovery is more rapid. In a morbidly obese patient, the narcotic-sparing 
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effect of dexmedetomidine was evident in the intraoperative and 
postoperative period after bariatric surgery. 
 Dexmedetomidine has been successfully used in the treatment of 
withdrawal of narcotics, benzodiazepines, alcohol, and recreational drugs. It 
is also used for procedural sedation in paediatric patients. 
 
Dosage and administration: 
 
For adults, dexmedetomidine is administered intravenously at a 
loading dose of 0.5 to 1 µg/kg as a slow infusion over a period of ten 
minutes, followed by a maintenance infusion of 0.2  to 0.7 µg/kg/hr.  
 
Dexmedetomidine should be diluted in 0.9 % normal saline for 
infusion. Dexmedetomidine is recommended for infusion lasting up to 24 
hrs. It is freely soluble in water. 
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Adverse effects: 
Major adverse effects include transient hypertension, hypotension 
haemorrhage, bradycardia, atrial fibrillation, sinus tachycardia, sinus arrest, 
ventricular tachycardia, myocardial infarction, agitation, confusion, 
delirium, hallucination, illusion and dry mouth. 
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      PHARMACOLOGY OF BUPRENORPHINE[18] 
 
Buprenorphine (CN-L-cyclopropyl methyl oripavin) is a potent 
semisynthetic highly lipophytic ring C bridge oripavine derivative of thebaine 
with narcotic agonist and antagonist activity. It is 25 to 40 times more potent 
than Morphine in analgesic effect. 
 
Chemical structure 
 Buprenorphine HCL is 17 cyclopropyl methyl α1,1-dimethyl ethyl 4,5-
epoxy-18,19-dihydro 3-hydroxy 6 methoxy -2-methyl-6,14 ethanomorphinan-7 
methanol hydrochloride. 
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PHARMACOLOGICAL ACTIONS 
(1) Central nervous system 
Buprenorphine produces typical dose related morphine like subjective 
effects. They are slower in onset but longer duration. Early receptor binding 
studies suggested that Buprenorphine was a selective mu receptor agonist. In 
rodents, the dose response curves for Buprenorphine induced analgesia and 
catalepsy is bell shaped. It has a high affinity for the mu, delta and kappa 
receptors. 
 
In receptor binding studies Buprenorphine behaves like an antagonist – 
Judged by the effect of Na++ ion affinity. Due to its no receptor agonist action 
it may cause symptoms of abstinence in patients who have been receiving 
Morphine like drugs. Buprenorphine is effective in relieving pain moderate to 
severe degree associated with surgical procedures, (Abdominal, thoracic, 
orthopaedic and hysterectomy) cancer pain neuralgias, renal colic, labour pain 
and myocardial infarction.  
 
It is more potent than morphine, pethidine, and pentazocine and the 
duration of analgesia is longer than all. Buprenorphine is relatively free from 
     
47 
 
dysphoria and psychotomimetic actions. Hallucinations  was produced in only 
0.9% of individuals. 
 
(2) Respiratory system 
The subjective respiratory depressant effects are unequivocally slower in 
onset and lasts longer than those of morphine. Maximum respiratory 
depression is observed at about 3 hours. Respiratory depression has not been 
observed in clinical trial.  
Significant respiratory depression appears to be dose related.  In 
anaesthetized patients Buprenorphine decreases both respiratory rate and 
volume. In postoperative period, Buprenorphine produces tendency towards 
respiratory acidosis and small decreases in respiratory rate (15%) and minute 
volume (16%). 
 
(3) Cardiovascular system 
In equivalent doses all the cardiovascular effects are similar to those of 
Morphine. There is significant reduction in heart rate (16%) with only minor 
decrease in systolic & diastolic pressure. In surgical or myocardial infarct 
patients, there is dose related decrease in systolic and diastolic pressure (10 to 
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25%), oxygen consumption (40%), left ventricular work (19%) and heart rate 
(24%) as well as compensatory increase in stroke volume. There is small 
decrease in pulmonary artery blood pressure. Myocardial contractility is not 
affected. It appears to be a safe analgesic for patients with a recent myocardial 
infarction. 
 
(4) Alimentary system 
It does not necessarily produce constipation. It causes nausea, vomiting 
in 10 to 20% of individuals. It increases intrabiliary pressure. 
 
REVERSIBILITY OF BUPRENORPHINE EFFECT 
 
By narcotic antagonist. 
Naloxone only partially reverses the respiratory depression produced by 
Buprenorphine, although this effect was temporarily reversible with a 
respiratory stimulant drug, Doxapram. Such treatment was apparently not 
completely satisfactory. 
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TOLERANCE, PHYSICAL DEPENDENCE AND LIABILITY FOR ABUSE 
In post addicts patients, subcutaneous dose of Buprenorphine doses 
(ranging from 0.2 mg to 2 mg) produce typical morphine like effects. 
Buprenorphine was given subcutaneously  for  40 to 50 days in a daily dose of 
8 mg. Subjects and observer identified Buprenorphine as a Morphine like 
agent.  
Subsequent administration of Naloxone did not produce abstinence 
syndrome. Buprenorphine resulted in very slowly emerging signs of 
withdrawal indicating a very long duration of action with very slow 
dissociation from opiate receptor sites. Overall potential for above of 
Buprenorphine is less than that of morphine. 
 
 PHARMACOKINETICS 
Absorption 
It is rapidly absorbed after intramuscular injection. Peak plasma levels 
are equal to those achieved with intravenous injection. Absorption is variable 
in sublingual dose. Average peak level is 3 hours and absorption completes 
within 5 hours. However, analgesia is attained within 15 minutes to 20 minutes 
and effect last longer than plasma levels. Thus appears to be no direct 
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relationship between plasma levels and pharmacological actions. 
Bioavailability  after sublingual dose in 50% occur with other strong analgesics 
such as Morphine, Pethidine, and Pentazocine. 
 
Precautions 
It may infrequently affect respiration and hence should be used with care 
in treating patients with impaired respiratory function. Ambulant patients 
should be warned not to drive car as it can cause drowsiness. As it has 
antagonist properties, it may precipitate withdrawal syndrome in narcotic 
addicts.  
The intensity and duration of action may be affected in patients with 
impaired liver functions. It should be used with caution in patients receiving 
MAO Inhibitors. It is relatively contraindicated in patients with head injuries. 
There is no absolute contraindications. It is not at present recommended in 
children and pregnant patients. 
 
Routes of administration– Sublingual, Parenteral, Intramuscular, Intravenous, 
Subcutaneous, through Brachial plexus block, Intrathecally, Epidurally. 
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USES   
Post operative pain. 
Premedication before surgery. 
 Component of balance anaesthesia. 
To reverse anaesthetic effects of fentanyl. 
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                                     REVIEW OF LITERATURE 
 
Mahima Gupta et al [27]  in 2013 conducted a double blinded study  to 
evaluate and compare the characteristics of subarachnoid blockade, 
hemodynamic stability and adverse effects of intrathecal buprenorphine and 
intrathecal dexmedetomidine as an adjuvant to 0.5% hyperbaric bupivacaine 
for lower abdominal surgeries. 
 Sixty patients were divided into two groups: Group B and Group D of 
thirty each. Group B received sixty µg of buprenorphine with 3 cc (15 mg) of 
0.5% heavy bupivacaine. Group D received 5 µg of Dexmedetomidine with 
3cc(15 mg) of 0.5% heavy bupivacaine.   
The onset of sensory and motor blockade in both Dexmedetomidine and 
buprenorphine were comparable. The duration of motor and sensory block in 
dexmedetomidine group was 413 minutes and 451 minutes which was 
significantly different from 205 minutes and 226 minutes of buprenorphine 
group. Similarly duration of analgesia was 493 minutes in dexmedetomidine 
group as compared to 289 minutes of buprenorphine group. 
 They concluded that intrathecal dexmedetomidine 5 µg when compared 
to intrathecal buprenorphine sixty µg causes prolonged duration of sensory and 
motor block.   
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The requirement of additional sedation and rescue analgesia is less in 
dexmedetomidine group and the haemodynamics are similar in both the groups 
without causing any significant side effects. 
Sapkal pravin S  et al [34] in 2013 conducted a study to evaluate and 
compare the efficacy, duration of post operative analgesia and adverse effects 
of intrathecal clonidine 60 µg and intrathecal Buprenorphine 60µg used as 
adjuvants in spinal anaesthesia for lower limb orthopaedic surgeries. 
 Total 80 male patients aged 20 to 60 years belonging to ASA grade I 
and II undergoing elective or emergency lower limb orthopaedic surgeries were 
randomly allocated into two groups. Group C received 3ml 0.5% bupivacaine 
with 60 µg clonidine, Group B received 3ml 0.5% bupivacaine with 60 µg 
buprenorphine. Duration of subarachnoid block , total analgesia, effective 
analgesia, number of rescue analgesics and adverse effects were assessed and 
compared in both groups.  
In group B , the duration of subarachnoid block is 161.3 ±13.9 minutes 
whereas in group C , the duration of subarachnoid block was 289.6±12.9 
minutes .In group B , the duration of effective analgesia was 818.9±135.5 
minutes whereas in group C , the duration of effective analgesia was 
686.5±41.9 minutes. In group  B , the duration of total analgesia was 
488.2±72.3 minutes whereas in Group C , the duration of total analgesia was 
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468.1±46.1 minutes. In group B , the nausea was noted  in 17.5% of patients, 
whereas  in group C , it was noted in 7.5% of patients. Vomiting was present in 
5% of patients in group B whereas none of the patients vomited in clonidine 
group. Somnolence was noticed slightly higher in buprenorphine group i.e., 
7.5% while 2.5% in clonidine group.  
This study concludes that intrathecal clonidine 60 µg significantly 
prolongs duration of spinal anaesthesia and quality of analgesia was acceptable 
to patients in both groups though VAS assessment was better in buprenorphine 
group. 
Alka shah et al [33] in 2012 conducted a study on 50 ASA 1 and 2 
patients planned for lower limb and lower abdomen  surgery. The  aim of this 
study was to evaluate the  hemodynamic effects intra operatively and the 
duration of postoperative analgesia. 
 Each patient received 0.75% isobaric  ropivacaine  4ml plus 5µg 
dexmedetomidine at the intervals of 1 minute, 2 minute, 5 minute, 10 minute, 
20 minute, 30 minute, and 1 hour, 2 hour and 3 hour reading of pulse rate and 
blood pressure were recorded. Postoperatively pain scores were recorded by 
using visual analogue scale. There were no significant changes in systolic and 
diastolic blood pressure after induction. This combination provides better 
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postoperative analgesia and reduced requirement of  diclofenac  injection in 
first 24 hours. 
 They concluded that 5µg dexmedetomidine seems to be an attractive 
alternative as an adjuvant to spinal ropivacaine in surgical procedures, 
especially those requiring long time. This combination  ( ropivacaine and 
dexmedetomidine) provides very good quality of hemodynamic stability. It has 
excellent quality of post operative analgesia with minimal side effects. 
Rajni Gupta et al [9] in 2011   Conducted a comparative study of 
intrathecal Dexmedetomidine and Fentanyl as adjuvants to Bupivacaine to 
evaluate the onset, duration of sensory and motor block, hemodynamic effect, 
post-operative analgesia and adverse effects. 
 Sixty patients scheduled for lower abdominal surgeries were randomly 
allocated into 2 groups of 30 each. Group D  recieved 12.5mg hyperbaric 
Bupivacaine with 5µg Dexmedetomidine. Group F received 12.5mg hyperbaric 
bupivacaine with  25 µg Fentanyl intrathecally.  
The mean time of sensory regression to S1 was 476 ± 23min in 
Dexmedetomidine and 187 ± 12 min in Fentanyl group. Regression to motor 
block was 421 ± 21min in Dexmedetomidine and 149 ± 18min in Fentanyl 
group. 
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 They inferred that intrathecal Dexmedetomidine is associated with 
prolonged motor and sensory block, hemodynamic stability, and reduced 
demand for rescue analgesics in 24 hours as compared to fentanyl. 
 
Hala E A Eid [29] et al in 2011  conducted a  prospective randomised  
double blinded study  to evaluate the effect of intrathecal administration of 
dexmedetomidine on the duration of sensory and motor block and 
postoperative analgesic requirements  produced by spinal bupivacaine. 
 Forty eight patients schedule for anterior cruciate ligament 
reconstruction were randomized to one of the three groups receiving 10µg 
Dexmedetomidine in first group, 15µg Dexmedetomidine in second group and 
normal saline in the third group with 3ml of 0.5% hyperbaric bupivacaine. 
Dexmedetomidine significantly prolonged time to 2 segment regressions, 
sensory regression to S1   regression of motor block to modified Bromage 0, 
time to first rescue analgesia and decreased post-operative pain scores.  
They concluded that intrathecal Dexmedetomidine in doses of 10µg and 
15µg significantly prolong the anaesthetic and analgesic effects of spinal 
hyperbaric Bupivacaine in a dose dependant manner. 
 
Shukla et al [32] in 2011 conducted a prospective randomised double 
blind study to evaluate the onset and duration of sensory and motor block, peri-
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operative analgesia and adverse effects of Dexmedetomidine and magnesium 
sulphate given intrathecally with 0.5% hyperbaric Bupivacaine for spinal 
anaesthesia. 
 90 patients of ASA Grade 1 and 2 scheduled for lower abdominal and 
lower limb procedures were prospectively studied. Patients were randomly 
allocated into 3 Groups of 30 each. Group D received 3 ml hyperbaric 
Bupivacaine + 0.1 ml (10 µg) Dexmedetomidine. Group M received 3 ml of 
hyperbaric Bupivacaine +
 
0.1 ml (50 mg) magnesium sulphate. Group C 
received 3 ml of hyperbaric Bupivacaine + 0.1 ml normal saline.  
The onset time to reach peak sensory and motor level, regression time 
for sensory and motor block, haemodynamic changes and side effects were 
recorded. The onset time of sensory block to reach T10 dermatome was 2.27 ± 
1.09 minutes in group D, 6.46 ± 1.33 in Group M and 4.14 ± 1.06 minutes in 
Group C. The onset time to reach Bromage 3 was 3.96 ± 0.92 minutes in Group 
D, 7.18 ± 1.38 minutes in Group M and 4.81 ± 1.03 in Group C. The regression 
time of sensory block was 352 ± 45 minutes in Group D, 265 ± 65 in Group M 
and 194 ± 55 minutes in Group C. The regression time of motor block
 
for 
Group D was 331 ± 35, 251 ± 51 for Group M and 140 ± 34 for Group C.  
There was no significant differences in the mean values and MAP the 
first hour after performing spinal anaesthesia and first hour in the PACU 
between 3 groups. The SPO2 was more than 95% in all patients in the 3 groups 
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either in the intraoperative or in the PACU time. 24 hours and 2 weeks 
following discharge, follow up did not show any neurological impairment 
related to spinal anaesthesia, back, buttock or leg pain, head ache or any 
neurological symptom.  
They concluded that intrathecal DXM supplementation of spinal block 
seems to be a good alternative to intrathecal Mg as it produces earlier onset and 
prolonged duration of sensory and motor block without associated significant 
haemodynamic alterations. 
     
Sheikh kiran et al [8] in 2010 conducted a prospective randomised 
double blind study to assess the efficacy 0f intrathecal buprenorphine for 
postoperative  pain relief  and to study the incidence of side effects. 
100 patients of  ASA 1 and 2 between the age group of 18- 60 years, 
who underwent surgery of the lower extremities and  lower abdomen were  
randomly  allocated into 2 groups of 50 each. Group A received 15 mg heavy 
bupivacaine plus 0.2  ml normal saline. Group B received 15 mg of heavy 
bupivacaine plus 1µg /kg of buprenorphine 0.2ml intrathecally  upto  a  
maximum of  50µg.  
The average time of onset of sensory block was 3.78 ± 0.97 min in 
Group A and 3.66 ± 1.008  in Group B. The mean duration of  analgesia was 
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195.2 ± 29.52 in Group A and 475.6 ± 93.7 in Group B.  The mean pulse rate  
at 0 min was 81.3 ± 7.91 in Group A and 79.16 ± 6.156 in Group B and the 
difference in pulse rate at 0,5, 10, 30 and 60 minutes respectively between both 
groups were not statistically significant. There were 5 cases of hypotension and 
1 case of nausea vomiting in Group A Whereas in Group B, there were 6 cases 
of hypotension, 2 cases of vomiting and 2 cases of shivering.  
They concluded that intrathecal Buprenorphine is an effective analgesic 
suitable for the management of postoperative pain.                            
          
Subhi M Al-Ghanem et al [31] in 2009 conducted a prospective 
randomised double blinded study to compare  the effect of adding 
Dexmedetomidine versus fentanyl to intrathecal 0.5% isobaric Bupivacaine on 
spinal characteristics in gynaecological procedures. 
 Seventy eight patients (ASA 1 to 3) were prospectively studied. Group 
D received isobaric bupivacaine 10 mg and Dexmedetomidine 5µg  (2.5ml) 
and Group F received isobaric bupivacaine 10 mg and fentanyl 25 microgram 
(2.5ml) . 
The onset time of sensory block to reach T10 was 7.5 ± 7.4 minutes for 
Group D and 7.4 ± 3.3 minutes  for Group F. The time to reach maximum 
sensory block was 19.34 ± 2.87 minutes for Group D and 18.39 ± 2.46 minutes 
for Group  F.  The onset time of motor block was 14.4 ±6.7 minutes in Group 
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D and 14.3± 5.7 minutes in Group F. The duration of motor block was 240 ± 
64 minutes in Group D and 155 ± 46 minutes in Group  F. The sensory 
regression to S1 segment was 274.8 ± 73.4 minutes in Group D and 179.5 
±47.4 minutes in Group F .The peak sensory level was T6 in both the groups.  
They concluded that 5 µg of dexmedetomidine seems to be an attractive 
alternative as adjuvant to spinal bupivacaine in surgical procedures especially 
in those that need quiet long time with minimal side effects and excellent 
quality of spinal analgesia. 
 
Mahmoud M Al-Mustafa et al [30]  in 2008 conducted a study to 
determine the effect of adding different doses of dexmedetomidine to isobaric 
bupivacaine for patients undergoing  urological procedures under spinal 
anaesthesia . 
 Sixty six patients were randomly assigned into 3 groups. Group N 
received Bupivacaine 12.5mg with saline. Group D5 received 12.5mg 
Bupivacaine with 5µg Dexmedetomidine. Group D10 received 12.5mg 
Bupivacaine with 10µg Dexmedetomidine. The mean time of sensory block to 
reach T10  dermatome  was 4.7 ±2 minutes in D10 group, 6.3 ±2.7 minutes in 
D5 group and 9.5 ± 3 minutes in Group N .  
The mean time to reach Bromage 3 scale was 10.4 ± 3.4 minutes in 
group D10, 13.0 ± 3.4 minutes in Group D5 and 18.0 ± 3.3 minutes in  Group 
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N. The regression time to reach S1 dermatome was 338.9 ± 44.8 minutes in 
Group D10, 277.1±23.2 minutes in D5 and 165.5 ± 32.9 minutes in Group N . 
The regression to Bromage 0 was 302.9± 36.7 minutes in D10 , 246.4± 25.7 
minutes in D5 and 140.1 ± 32.3 minutes in Group N. Onset and regression of 
sensory and motor block were highly significant (N verses D5,N verses D10 
and D5 verses D10).  
They concluded that dexmedetomidine has a dose dependent effect on 
the onset and regression of sensory and motor block when used as an adjuvant 
to bupivacaine in spinal anaesthesia.  
 
F A Khan et al [36] in 2006 conducted a study to evaluate and compare 
the characteristics of spinal block, its postoperative analgesic effects and its 
side effects using intrathecal bupivacaine with fentanyl or buprenorphine in 
elderly patients undergoing urological surgeries. 
 Sixty patients aged sixty and above scheduled for elective transurethral 
resection of prostate were divided into three groups of 20 each. Group L 
(control) received 2 ml of 0.75% bupivacaine. Group B received 2 ml of 0.75% 
bupivacaine with 30 µg buprenorphine. Group F received 2 ml of 0.75% 
bupivacaine  with  10 µg fentanyl.  
The mean time for the sensory block to reach T10 level was 3.2 ± 2 
minutes in Group F and 4.3 ± 1 minute in Group B and 4.5 ± 2 minutes in 
     
62 
 
Group L. The duration of sensory block was significantly longer in Group B. 
Median block levels reached T8 in all groups. All patients required 
postoperative analgesia in Group L and F except six patients in buprenorphine 
group.  
They concluded that buprenorphine 30 µg in combination with 
bupivacaine   0.75%  2 ml provided analgesia of comparable clinical onset and 
longer duration but was associated with a clinically increased incidence of 
nausea and vomiting in elderly patients.  
 
 G.E.Kanazi et al [14]  in 2005 conducted a prospective, double blind 
study in 60 patients undergoing transurethral resection of prostate or bladder 
tumour under spinal anaesthesia. The   aim  was  to  compare  the onset and 
duration of sensory and motor block, hemodynamic changes and level of 
sedation following intrathecal administration of bupivacaine with either 
dexmedetomidine or clonidine. 
 60 patients were randomly allocated into 3 Groups. Group B received 
12 mg of  hyperbaric bupivacaine, Group D received 12 mg of bupivacaine of 
supplemented with 3µg of dexmedetomidine, Group C  received 12 mg of  
bupivacaine supplemented with 30µg of clonidine.  
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The onset time to reach peak sensory and motor levels and the sensory 
and motor regression times were recorded. Haemodynamic changes and the 
level of sedation were also recorded. The mean time to reach T10 sensory 
block was 9.7 ± 4.2 minutes in Group B, 7.6 ± 4.4 minutes in Group C, 8.6 ± 
3.7 in Group D. The mean time to reach peak sensory level was 20.2 ± 8.4 
minutes in Group B, 18.7 ± 9.2 minutes in Group C, 24.5 ± 14.8 minutes in 
Group D. The mean time to reach Bromage 3 was 13.2 ± 5.6 in Group D, 11.7 
± 5.9 minutes in Group C, 20.7 ± 10.3 minutes in Group B. The mean values of 
MAP and heart rate were comparable between 3 Groups throughout the intra 
op and post-operative period. All patients had oxygen saturation > 96% at all 
times and did not require additional oxygen in PACU.  
They concluded that supplementation of spinal Bupivacaine with low 
dose of intrathecal Dexmedetomidine or clonidine produces significantly 
shorter Onset of motor block and significantly longer sensory and motor block 
than bupivacaine alone. Dexmedetomidine 3µg and Clonidine 30µg have a 
equipotent effect on the characteristics of the block without any significant 
hemodynamic instability or sedation. 
 
    Talke et al  [35] in 1997 conducted a randomised double blind study in nine 
male volunteers .Dexmedetomidine was administered by computer controlled 
infusion, targeting its plasma concentration at 0.0,0.3,0.6 ng/ml. Each day skin 
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and core temperature were increased to provoke sweating and then 
subsequently reduced to elicit vasoconstriction and shivering. The dose 
dependant effects of dexmedetomidine on thermoregulatory response threshold 
were then determined using linear regression. Heart rate, blood pressure and 
plasma catecholamine levels were measured. 
 They concluded that dexmedetomidine markedly increased the range of 
temperature not trigerring thermoregulatory defence and it is likely to prove an 
effective treatment for shivering. 
 
Capogna et al [11] in 1988 conducted a double blind study to determine 
the effects of two doses of intrathecal Buprenorphine for post-operative pain 
relief in elderly patients. 90 patients aged 56 to 85 years scheduled for 
suprapubic prostatectomy were randomly divided into 3 groups of 30 each.  
Group A received 30 mg of hyperbaric Bupivacaine. Group B received 
30 mg hyperbaric Bupivacaine plus 0.03 mg of Buprenorphine. Group C 
received 30 mg hyperbaric bupivacaine + 0.045 mg of buprenorphine. The 
mean pain free interval was 103.45 minutes in Group A (control group),183.06 
minutes in Group B, 430.16 minutes in Group C. In Group B pain increased 
gradually from 5 - 8 hours. In Group C pain increased from 7 - 12 hours. The 
mean respiratory rate in all 3 groups during the first12 hours remains stable. In 
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Group C respiratory rate transiently decreased below 10 breaths per minute in 
one patient, but no treatment was required.  
Heart rate and blood pressure remained within the physiological range 
during the observational time. Nausea and vomiting occurred in 11 Patients 
who received 0.03 mg buprenorphine and in 14 patients who received the 
larger dose.  
They concluded that intrathecal buprenorphine provided postoperative 
analgesia with minimal disturbance of consciousness,  Comfortable breathing 
and reduced the risks of postoperative complications. Intrathecal administration 
of  buprenorphine 0.03 mg or 0.045 mg may be used for postoperative 
analgesia in elderly patients. The higher concentration offers more prolonged 
analgesia without any further significant increase in side effects. 
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MATERIALS AND METHODS 
 
Study design:  Double blinded randomised case control study. 
 
  After obtaining approval from the institutional ethical committee, 
Thanjavur medical college, Thanjavur, the study was conducted in 60 ASA 
grade 1 or 2 patients undergoing elective lower abdominal surgeries like 
Hernia repair and appendicectomy under spinal anaesthesia. Before including 
the patients for the study, all patients were explained about the procedures and 
a written informed consent was obtained. 
 
 
INCLUSION CRITERIA: 
 Adult patients aged 18 - 60 years of either sex 
 ASA 1 and 2 patients. 
 Patients undergoing elective lower abdominal surgeries. 
 
 
EXCLUSION CRITERIA: 
 Patients with known contraindication for spinal anaesthesia. 
 Patients with coagulation disorders or on anticoagulation therapy. 
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 Patients with cardiac disease, heart blocks and dysarrythmias   
 Patients with betablockers & alpha antagonists. 
 
 
  PREOPERATIVE PREPARATION: 
          After routine preoperative assessment at the patients’ waiting room in the 
OT, basal line readings of the vital parameters were recorded. Intravenous line 
started. The patients were randomly allocated into two groups of 30 each by 
using closed cover technique. 
       In the operating room, appropriate equipment for airway management and 
emergency drugs were kept ready. The horizontal position of the operating 
table was checked. Patients were shifted to the operating room and positioned. 
      Non-invasive blood pressure monitor, pulse oximeter and ECG leads were 
connected to the patient. Preoperative baseline systolic and diastolic blood 
pressure, mean arterial pressure, pulse rate, respiratory rate and oxygen 
saturation were recorded. Patients were preloaded with 10ml/kg of ringer 
lactate 15minutes prior to the subarachnoid block. On sitting position, the skin 
over the back was prepared with antiseptic solution and draped with sterile 
towel. 
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 BD GROUP 
 
 Patients received 3ml 0.5% bupivacaine (15mg) 
 Dexmedetomidine (5µg) in 0.5 ml normal saline. 
 
 
BB GROUP 
 Patients received 3ml 0.5% bupivacaine(15mg) 
 0.5ml Buprenorphine (75µg) 
 
Total volume of the injected solution was 3.5ml in both groups. 
 
 
 After skin’s infiltration with 2% lidocaine, 25G Quincke’s needle was 
inserted at the L3/4 interspace in the midline. After confirming free flow of 
CSF, the prepared solution was injected. The patients were made to lie supine 
immediately after injection and the time at which the spinal anaesthesia 
performed was noted. 
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The following parameters were noted. 
  Time of injection of subarachnoid block. 
  Time of onset of sensory block at T8 level. 
  Time of onset of motor block. 
  Duration of sensory block. 
  Duration of motor block. 
  Degree of sedation. 
  Time for sensory regression to S1 dermatome. 
  Duration of surgical procedure. 
 
  Systolic and Diastolic blood pressure, Mean Arterial Blood 
pressure, pulse rate and oxygen saturation were recorded at 0, 3rd  
and 5th minute  and thereafter every 5 minutes upto 45 minutes of 
the procedure.  
 
  Hypotension was said to have occurred if the MAP fell less than 
60 mmHg and treated with 100% O2, increasing the infusion rate 
of IV fluids and Inj. Ephedrine in incremental doses of 6mg at 
interval of 2 minutes. 
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  Bradycardia was defined as heart rate less than 50/min and was 
planned to be managed with intravenous atropine in incremental 
doses. 
  Respiratory depression was said to be present if respiratory rate 
was less than 8/minute and / or Spo2 < 90%. It was planned to be 
managed with mask ventilation or intubation and IPPV. 
  Any discomfort like nausea, vomiting, shivering, pruritus and 
adverse events such as hypotension, bradycardia respiratory 
depression and ECG changes were noted. 
  Vomiting was planned to be managed with Inj.Ondansetron 4mg 
intravenously. 
  On completion of surgery, patient was shifted to post anaesthesia 
care unit for observation. Patients were transferred to 
postoperative ward after complete resolution of motor blockade 
and stabilization of blood pressure.  
  Vital signs and oxygen saturation were recorded until recovery of 
patients from anaesthesia. 
  Injection Diclofenac sodium 75mg was given intramuscularly 
when the patient complained of pain in the postoperative period 
(rescue analgesic). 
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  Patients were followed up for one week postoperatively for 
headache, dysaesthesia in thighs, buttocks or lower limbs. 
 
 
SENSORY BLOCK  
The onset of sensory block was defined as the time between the injection 
of anaesthetic solution and the absence of pain at the T8 dermatome. Sensory 
block was assessed by loss of sensation to pin prick using 25G sterile needle 
bilaterally along the midclavicular line. This assessment started immediately 
after turning the patient to supine position and continued every minute till loss 
of sensation to pinprick at T8 level was noted.  
The duration of sensory block was defined as the time between the 
intrathecal administration of anaesthetic solution and the first supplementation 
of rescue analgesic when patient complained of pain. 
 
 
MOTOR BLOCK 
    Motor block was assessed bilaterally using Modified Bromage scale. 
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MODIFIED BROMAGE SCALE 
0- No block. Able to raise extended legs against gravity. 
1- Unable to raise extended legs, but just able to flex knees. 
2- Unable to flex knees but able to flex ankles. 
3- Total block. Inability to flex ankle/ move leg. 
Assessment of motor block was started immediately after turning the 
patient to supine position and continued every minute till Bromage score of 3 
was reached. The onset of motor block was defined as the time to achieve 
Bromage score of 3 from the time of intrathecal injection. Duration of motor 
block was taken as the time from intrathecal injection to return of Bromage 
score of 0 (complete recovery). 
 
SEDATION 
RAMSAY SEDATION SCORE was used to assess the degree of sedation. 
1. Anxious and Agitated. 
2. Cooperative, oriented, tranquil 
3. Responds only to verbal commands  
4. Asleep with brisk response to light stimulation 
5. Asleep with sluggish response to light stimulation 
6. Asleep without response to light stimulation 
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DURATION OF ANALGESIA  
  The duration of effective analgesia was defined as the period from 
spinal injection to the first occasion when the patient complaints of pain in the 
postoperative period.                      
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              OBSERVATION AND ANALYSIS 
 
All 60 patients in two groups completed the study without any exclusion. 
Inter group analysis was done and the results were as followed.  
 
       The collected data were analysed by chi square test and results obtained in 
the form of range, mean and standard deviation. The probability value ‘p’ of 
less than 0.05 considered statistically significant. 
        
Patient demographic data that includes age, sex, and duration of surgery 
between two groups were comparable. 
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Table 1:  Age distribution 
Age in years 
Group BB Group BD 
 
Age group 
No. % No. % 
Below 30 years 6 20 8 26.7 
31 – 40 9 30 6 20 
41 – 50 6 20 9 30 
Above 50  9 30 7 23.3 
Total 30 100 30 100 
Range 19 – 60 years 18 – 60 years 
Mean 42.33  40.57  
SD 12.88  13.22 
‘p’ value 0.875 
Not significant 
 
 The age distribution was in the range of 19-60 in Group BB and 18-60 
in Group BD. The ‘p’ value for mean age was not statistically significant (p 
value = 0.875). 
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AGE DISTRIBUTION 
 
 
                
 
 
 
 
 
20 
30 
     
77 
 
 
 
Table 2: Sex distribution 
 
 
Group BB Group BD  
Sex No % No % 
Male 25 83.3 23 76.7 
Female 5 16.7 7 23.3 
Total 30 100 30 100 
‘p’ 0.752 
Not significant 
 
 
Though male and female ratio is not equal in either group, statistics 
between the groups for sex distribution was not significant.  The p value is 
0.752. 
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  EFFICACY OF THE TWO DRUGS 
Table 3:  Time of onset of sensory block 
 
 
 The time of onset of sensory block was slower in Group BB (3.47± 
0.507) when compared with Group BD (2.57± 0.504) and the p value was 
statistically not significant (0.629 > 0.05).    
 
Time of onset of sensory block 
(in minutes) 
 
Parameter 
Group BB Group BD 
Range 3-4 2-3 
Mean 3.47 2.57 
SD 0.507 0.504 
‘p’ value 
0. 629 
Not Significant 
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Table 4:  Time of onset of motor block 
Time of onset of motor block 
(in minutes) 
 
Parameter 
Group BB Group BD 
Range 3-5 3-5 
Mean 3.83 4.13 
SD 0.817 0.78 
‘p’ value 
0. 775 
Not Significant 
 
  The average time taken for the onset of motor block was 3.83 minutes in  
Group BB and 4.13 minutes in Group BD. It was statistically not significant (p 
value 0.775 > 0.05).  
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Table 5:  Duration of Sensory block 
 
Duration  of Sensory block 
(in minutes) 
 
Parameter 
Group BB Group BD 
Range 303-360 480 – 520 
Mean 332 502.13 
SD 18.81 12.27 
‘p’ value 
0. 005 
Significant 
 
The mean duration of sensory block was shorter in Group BB (332 ± 
18.81) when compared with Group BD (502.13 ± 12.27). It was statistically 
significant (p value= 0.00 < 0.05). The mean duration of sensory block in 
Group BD is approximately 51% longer than Group BB.  
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Table 6:  Duration of motor block 
 
Duration of motor block 
(in minutes) 
 
Parameter 
Group BB Group BD 
Range 293-360 413-460 
Mean 298.63 432.33 
SD 35.79 12.74 
‘p’ value 
0. 000 
Significant 
 
The mean duration of motor block was shorter in Group BB (298.63 ± 
35.79) when compared with Group BD (432.33 ± 12.74). It was statistically 
significant (p value = 0.00 < 0.05). The mean duration of motor block in Group 
BD is about approximately 44% longer than Group BB. 
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Table 7:  Time of sensory regression to S1 
 
Time of sensory regression to S1 
(in minutes) 
 
Parameter 
Group BB Group BD 
Range 250-299 389-409 
Mean 272.27 398.1 
SD 15.39 6.50 
‘p’ value 
0. 001 
Significant 
 
The time of   sensory regression to S1 was shorter in Group BB (272.27 
± 15.39) when compared with Group BD (398.1 ± 6.50). It was statistically 
significant (p value = 0.048 < 0.05). There was a delay in sensory regression of 
approximately 1/3 times (30%) in Group BD comparing to Group BB. 
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HAEMODYNAMIC VARIABLES 
 
                Table 8: Mean arterial Pressure 
Time Interval BB Group  (Mean ± SD) 
BD Group  
(Mean ± SD) P value 
0  min 81.23 ± 10.45 80.17 ± 10.45 0.963 
3  min 80.57 ± 13.35 80.90 ± 10.47 0.089 
5  min 75.63 ± 14.47 80.33 ± 13.79 0.854 
10  min 78.60 ± 13.71 83.20 ± 12.63 0.897 
15  min 75.07 ± 11.96 78.97 ± 12.75 0.337 
20  min 81.17 ± 13.09 79.53 ± 13.21 0.780 
25  min 79.60 ± 10.83 79.60 ± 10.61 0.958 
30  min 74.50 ± 10.86 76.97 ± 11.53 0.406 
35  min 82.13 ± 12.96 83.47 ± 11.56 0.222 
40  min 77.60 ± 10.93 76.43 ± 11.08 0.663 
45  min 78.43 ± 11.50 77.57 ± 12.10 0.503 
 
The mean arterial pressure was monitored from preoperative basal to 45th 
minute of the procedure (11 intervals). None of the intervals had statistical 
significance. 
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Table 9: Heart rate 
Time Interval BB Group  (Mean ± SD) 
BD Group  
(Mean ± SD) P value 
0  min 78.93 ± 12.21 77.43 ± 9.16 0.035* 
3  min 81.47 ± 13.37 74.27 ± 9.13 0.000* 
5  min 80.63 ± 12.79 81.07 ± 11.55 0.360 
10  min 78.37 ± 13.96 80.33 ± 11.89 0.769 
15  min 77.73 ± 15.92 77.80 ± 12.18 0.083 
20  min 79.23 ± 13.13 82.40 ± 13.49 0.806 
25  min 79.77 ± 12.05 78.57 ± 12.43 0.668 
30  min 80.93 ± 12.50 79.87 ± 12.58 0.684 
35  min 79.90 ± 11.72 78.17 ± 11.21 0.584 
40  min 79.70 ± 12.15 80.73 ± 11.36 0.442 
45  min 77.23 ± 11.98 76.37 ± 11.98 0.874 
 
In this study, heart rate less than 50 beats was considered as bradycardia 
while collecting the data. Heart rate was recorded in 11 intervals, out of which 
only 2 intervals (0 and 3rd minute) were statistically significant (*). 
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Table 10:  SPO2 
 
SPO2  
Parameter 
Group BB Group BD 
Range 97-100% 97-100% 
Mean 98.53 98.43 
SD 1.008 1.006 
‘p’ value 
 
0.972 
Not significant 
 
Oxygen saturation was in the range of 97 – 100 %. It was not statistically 
significant (p value 0.972 > 0.05). 
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Table 11:  Degree of Sedation 
 
Degree of Sedation 
(Ramsay sedation scale) 
 
Parameter 
Group BB Group BD 
Range 1-3 2-3 
Mean 1.83 2.40 
SD 0.791 0.498 
‘p’ value 
0. 018 
Significant 
 
In table 11, Degree of Sedation in the two groups was depicted. ‘p’ value 
was statistically significant (0. 018 < 0.05). Degree of Sedation was better in 
Group BD when compared with Group BB. 
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Table 12:  Adverse effects 
 
Group BB Group BD 
Adverse effects 
No % No % 
Hypotension 8 27 0 0 
Bradycardia 6 20 2 7 
Shivering 3 10 0 0 
Nausea &Vomiting 3 10 0 0 
Total cases with adverse 
effects 
20* 67 2 7 
Total cases without adverse 
effects 
10* 23 28* 93 
Total 30* 100 30* 100 
                                            
* More than one adverse effect was present in one case in each group  
In Group BB, 8 patients (27%) had hypotension and received ephedrine.  
In Group BD, none of the patients had hypotension as an event. But these 
episodes were not statistically significant (refer to table 8). Other adverse 
effects between the two groups were comparable. 
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DISCUSSION 
 
Subarachnoid block with bupivacaine has been most extensively used for 
lower abdominal surgeries because of its simplicity, speed, reliability and 
minimal exposure to depressant drugs. However, a single intrathecal injection 
of bupivacaine alone provides analgesia for only 2 – 2.5 hours. Most patients 
require further analgesia during post operative period. 
This double blinded, prospective, randomised study was conducted in 
Thanjavur  medical college,   Thanjavur  with an aim to compare the effects of 
intrathecal Dexmedetomidine and Buprenorphine as an adjuvant to 0.5% 
hyperbaric bupivacaine. 
The study included 60 patients belonging to the age group of 18-60 years 
of both sexes of ASA grade 1 and 2 scheduled to undergo elective lower 
abdominal surgeries.  
         One of the study drugs,   Buprenorphine, a highly lipophilic and centrally 
acting partial opioid agonist has rapid onset of action following intrathecal 
administration. It has been found recently that prolonged duration of action of 
buprenorphine is due to its local anaesthetic action [37]. The lesser side effects 
in the post-operative period were due to its high lipid solubility [38]. 
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 Because of its high lipophilic nature, it diffuses quickly into the neural tissue 
and decreases the chance of rostral spread. 
 
Another drug in the study, Dexmedetomidine which is a specific α2 
adrenergic agonist, being used in recent times as an additive to intrathecal 
hyperbaric bupivacaine to prolong the quality and duration of analgesia. The 
mechanism for the prolongation of the duration of sensory and motor blockade 
produced by local anaesthetic is not clearly known [33]. It is attributed that   α 2 
adrenergic agonist (Dexmedetomidine) acts by binding to post synaptic dorsal 
horn neurons and to the C- fibres in the pre synaptic region. The prolonged 
analgesic action of intrathecal α2 agonist is by decreasing the release of C- 
fibres neurotransmitters and by causing hyperpolarisation of neurons in the 
post synaptic dorsal horn [39]. 
Even though there are lot of adjuvants, the above mentioned two 
adjuvants were considered for this study because there were only very few 
studies in the literature comparing the benefits and side effects of 
buprenorphine and dexmedetomidine as an adjuvants to bupivacaine for lower 
abdominal surgeries [27]. Also, they are pharmacologically different drugs but 
their effects are similar in terms of hemodynamic stability, onset of sensory 
and motor block and adverse effects [27]. 
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But these two drugs differ in the clinical effects especially in the 
duration of sensory and motor block, sensory regression and degree of 
sedation[27] . 
 Kanazi GE et al [14] have used 3 µg dexmedetomidine in their study and 
said to have comparable equipotent effect with clonidine.  Hala EA Eid et al [29] 
studied the effects of dexmedetomidine on a dose related manner (control, 10 
µg and 15µg) and confirmed the prolongation of duration of analgesia. Many 
studies have chosen 5µg of dexmedetomidine as an additive to intrathecal 
hyperbaric bupivacaine and proven efficacy [9,30]. Hence in our study we chose 
5µg dexmedetomidine as an additive to hyperbaric bupivacaine.  
 
 Few studies have been conducted with a higher dosage of 
buprenorphine. Capogna et al [11], Mahima gupta et al [27] and sapkal 
Praveen S et al [34], have chosen 60µg of buprenorphine as an additive to 
intrathecal bupivacaine and showed to have a significant prolonged duration of 
analgesia along with nausea and vomiting that were not statistically significant.  
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Mahima gupta et al[27] also shown the duration of sensory blockade was 
289.6 minutes in buprenorphine group and 493.6 minutes in dexmedetomidine 
group. 
 In this study, 75µg of buprenorphine was used instead of 60µg to 
evaluate whether the increased dosage of 15µg buprenorphine would help in 
further prolongation of duration of analgesia with a minimal side effects 
(PONV).   
The results of the clinical study are discussed under the following 
headings. 
 
Onset of sensory and motor block. 
Duration of sensory block. 
Duration of motor block. 
Time for sensory regression to S1 
Hemodynamic stability and  
Adverse effects. 
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ONSET OF SENSORY AND MOTOR BLOCK 
        The mean onset of sensory block in buprenorphine group was 3.47 
minutes whereas in dexmedetomidine group it was 2.57 minutes. It was not 
statistically significant.  
     The mean onset of motor block in buprenorphine group was 3.83 minutes 
whereas in dexmedetomidine group, 4.13 minutes. It was not statistically 
significant.  
     Though the values of onset of motor blockade is similar to  Mahima gupta 
et al[27] and others, the onset of sensory blockade of dexmedetomidine group 
was clinically faster than buprenorphine group in our study which could not be 
explained. 
   
DURATION OF ANALGESIA 
        Duration of analgesia was taken from the time of intrathecal injection of 
drugs to the first supplementation of rescue analgesic when patient complained 
of pain. In our study, the mean duration of analgesia was 332 minutes in 
buprenorphine group and 502.13 minutes in dexmedetomidine group.  
           The duration of analgesia in the Buprenorpine Group was 332 minutes 
whereas in the study conducted by Mahima gupta et al[27] it was 289.66 ± 
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68.94. The prolongation of duration in our study could be explained by the 
dosage difference of buprenorphine (75 µg Vs 60µg). But the mean duration of 
analgesia  in the studies conducted by Shaikh and Kiran et al[8]  and Capogna 
et al [11]was 475 minutes and 430 minutes respectively which is very high than 
our study. This gross difference might be explained by the geriatric group of 
patients in Capogna et al and lower limb surgeries included in Safiya et al as 
noted by Mahima gupta et al. 
 The duration of analgesia in the dexmedetomidine group in the study 
conducted by Mahima gupta et al[27] was 493 minutes and the study conducted 
by Shah et al[33] was 474 minutes. The duration of analgesia was significantly 
prolonged in the study done by Rajni Gupta et al[9] (478 minutes). In our 
study, the mean duration of analgesia was 502.13 minutes in dexmedetomidine 
group which was similar to above mentioned studies. Also, the study done by 
Eid et at al[29] showed that duration of analgesia with dexmedetomidine Group 
was proportional to its dose.  
  In this study, Dexmedetomidine group had prolonged duration of 
analgesia compared to Buprenorphine group which was 51% higher than the 
later. Mahima Gupta et al [27] have shown similar results. The prolonged 
analgesic action of intrathecal α2 agonist is by decreasing the release of C- 
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fibres neurotransmitters and by causing hyperpolarisation of neurons in the 
post synaptic dorsal horn [39]. 
 
DURATION OF MOTOR BLOCK 
  The duration of motor block was taken from time of intrathecal 
drug administration to the time taken to attain modified bromage 3. The mean 
duration of motor block in Buprenorpine group was 298.6 minutes and in 
dexmedetomidine group was 432.33 minutes (p value 0.00). 
  This was similar with the study conducted by Mahima gupta et al 
[27] 
, where the duration of motor block in dexmedetomidine group was 413.4 
minutes and the study conducted by Rajni Gupta et al[9] , where the duration of 
motor block was 421 minutes.  
                 The mean duration of motor block in buprenorphine group is 298.6 
minutes, whereas the duration of motor block in Mahima gupta et al [27] study 
was 205.17 minutes which is significantly lower than our study. This could be 
explained by the increased dosage used in our study. 
 In our study itself, motor blockade in dexmedetomidine group was about 
45% prolonged than Buprenorpine group. Such a prolongation of motor 
blockade may not be liked by many patients who have undergone surgeries that 
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would end by one hour. In this perspective, Buprenorphine would be a better 
adjuvant. Also, the duration of ‘pure’ sensory blockade (after the wear of motor 
blockade effect) in dexmedetomidine group was twice that of buprenorphine 
group (70 Vs 34 minutes). Still, Dexmedetomidine is a better drug as it would 
spare the rescue analgesic requirements.  
 
 
TIME FOR SENSORY REGRESSION TO S1 
         The mean duration for sensory regression to S1 in buprenorphine group 
was 272.27 minutes and in dexmedetomidine group, 398.1 minutes.  
In a study conducted by Mahima gupta et al [27], the mean duration for 
sensory regression to S1 in buprenorphine group was 225.9 min which was 
lower than the same group in our study. But in dexmedetomidine group it was 
451.4 min that was higher than the same group in our study. 
 Subhi  M Al-ghanem et al[31]  showed that the mean duration for 
sensory regression to S1 dermatome was 274.8 minutes in dexmedetomidine 
group which was lower than our study. This may be because of the higher 
volume (3 ml) of a hyperbaric solution probably prolonged the regression time 
comparing to the lower volume (2ml) of isobaric solution in their study. 
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      Rajni gupta et al  [9] have shown that the mean time for sensory regression 
to S1 was 476 min in dexmedetomidine group which is higher than our study. 
This may be because either the usage of higher concentration( 0.75%) of 
isobaric ropivacaine or due to the potentiation of intrathecal ropivacaine by 
intrathecal dexmedetomidine[40]. 
 S1 dermatome is used as the sensory regression point in most of the 
studies  [9,  27]. S1dermatome is well below the dermatomes those are involved 
in the surgery (T8 – L1) in our study. But patients in both groups never 
complaint of pain at the time of sensory regression to S1. More than that, 
analgesia was extended to the time for first analgesic requirement. This is the 
classical effect of adding an adjuvant to the local anesthetics i.e improving 
patients’ comfortness and reducing both the postoperative analgesic 
requirement and side effects.  
In this purview, in our study dexmedetomidine is superior to 
buprenorphine in having prolonged duration of sensory block, duration of 
motor block and sensory regression to S1.  
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HAEMODYNAMIC STABILTY 
   Al-Ghanem et al[31] in their study noted that the use of intrathecal 
dexmedetomidine to be associated with decrease in blood pressure and heart 
rate. 
 In the present study,  it was noted  2 cases of bradycardia and nil cases 
of hypotension in dexmedetomidine group whereas 6 cases of bradycardia and 
8 cases of hypotension in buprenorphine group. They were managed 
successfully with the use of atropine 0.6 mg I.V and ephedrine in incremental 
doses of 6 mg.  
 
    Bradycardia at 0 and 3 minute interval in dexmedetomidine group had 
the statistical significance.   
 
     Mahima gupta et al [27]in their studies also incidence of bradycardia was 
more in dexmedetomidine group. Dexmedetomidine causes bradycardia but the 
effect is more prominent when administered intravenously and with a higher 
dose[44]. 
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DEGREE OF SEDATION 
         There were significant differences between the two groups with respect 
to the degree of sedation as evidenced by the significance value obtained from 
the chi square test that was less than 0.05. The need for further intraoperative 
sedation was nil in dexmedetomidine group. 
          
Mahima gupta et al[27] in their study noted  that  the sedation score was higher 
in patients belonging to dexmedetomidine group as compared  to 
buprenorphine group which is similar to our study. This was due to the action 
of dexmedetomidine on α2 receptors on locus ceruleus. 
 
ADVERSE EVENTS 
 The incidence of nausea and vomiting were more in buprenorphine 
group as compared to dexmedetomidine group which is similar to the study 
conducted by Mahima gupta et al [27].  Capogna et al[11] also observed more 
number of nausea and vomiting in buprenorphine group. Similar observations 
were seen by sapkal et al[34].  
Talke et al[35] in their study observed that α2 adrenergic agents have anti 
shivering property. In the present study we have not encountered any case of 
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shivering. This is in contrast to Mahima gupta et al[27] study where the 
incidence of shivering was more in dexmedetomidine group when compared to 
buprenorphine group. 
 
In the present study the SPO2 was in the range of 97 – 100 % without 
oxygen supplementation. No incidence of respiratory depression, pruritus and 
ECG changes were found in both the groups.  
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                                                 SUMMARY 
 
A clinical study was undertaken to compare the effects of intrathecal 
Buprenorphine and dexmedetomidine as additives to 0.5 % hyperbaric 
bupivacaine for spinal anaesthesia. This prospective, randomized, Double blind 
study was conducted on 60 adult patients of ASA physical status 1 and 2 in the 
age group of 18 to 60 years, posted for elective lower abdominal surgeries at 
Thanjavur Medical college Hospital, Thanjavur from the period June 2012 – 
July 2014. 
 
 Patients were randomly allocated into two groups namely, Group BB 
and Group BD of 30 each. 
 
Patients in Group BB received 75mcg of Buprenorphine with 0.5% 
bupivacaine 15mg intrathecally. 
          Patients in Group BD received 5mcg of Dexmedetomidine with 0.5% 
bupivacaine 15mg intrathecally. 
After connecting monitors, the required preloading done to all patients. 
Subarachnoid block was carried out under aseptic precautions. Pulse rate, 
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respiratory rate, arterial blood pressure and oxygen saturation were recorded  at 
0, 3, 5 minutes and thereafter every 5minutes up to 45 minutes  
intraoperatively.  
 
 The following parameters were observed - onset and duration of sensory 
block and motor block, time for sensory regression to S1, degree of sedation, 
hemodynamic stability and any side effects associated with these drugs. 
 
Collected data were analysed using appropriate statistics. 
 
Demographic datas were not statistically significant. The onsets of 
sensory and motor blockades were not statistically significant. The duration of 
sensory blockade was prolonged in dexmedetomidine group (51%) compared 
to buprenorphine group that was similar to Mahima  gupta et al [27]. The Motor 
blockade, sensory regression to S1 were also got prolonged in 
Dexmedetomidine group which was also proven by Rajni gupta et al [9]. The 
degree of sedation was better in dexmedetomidine group than buprenorphine 
group. 
(Ramsay sedation score of 3). Hemodynamic parameters were comparable 
between the groups. 
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 CONCLUSION   
 
 The present study concludes that 
 
1. The onsets of sensory and motor blockades were not statistically 
significance between the groups. 
          2. The duration of both sensory and motor blockades were prolonged in 
dexmedetomidine group compared to buprenorphine group with the best 
statistical significance. 
          3. Both groups had stable and comparable hemodynamics during the 
study.  
4. Compared to buprenorphine, intrathecal administration of 
dexmedetomidine as additive to hyperbaric bupivacaine was associated with 
fewer side effects. 
5. The degree of sedation was better in the dexmedetomidine group 
when compared to buprenorphine group. 
 
 
 
z 
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                                                      PROFORMA 
 
Name  :      IP  no                    :  
Age       :     Diagnosis              : 
Sex  :     Procedure                   : 
Weight         :                       ASA   physical status    : 
MPG           :              Duration of surgery      :  
  
 
PREOPERATIVE OBSERVATIONS: 
GENERAL PHYSICAL EXAMINATION            SYSTEMIC EXAMINATION 
 Pulse rate     :      CVS       : 
Bp                  :      RS : 
Spo2              : 
GROUP                                                          :  D/B 
Position & site of injection              : 
Time of intrathecal injection of drug             : 
Time of onset of sensory block (min)            : 
Time of onset of motor block (min)                : 
Time for modified bromage 0(min)            : 
Duration of analgesia (min)             : 
Time for sensory regression to s1 dermatome : 
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Degree of sedation (<3/>3)                  :              
 
 
 
 
INTRAOPERATIVE HEMODYNAMIC CHANGES: 
PARAME
TERS 
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in 
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15
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min 
35
min 
40
min 
45
min 
  H.R            
  SBP            
 DBP            
MAP            
SPO2            
 
SIDE EFFECTS AND COMPLICATIONS: 
Nausea/vomiting   : 
Shivering   : 
Ephedrine required : 
Atropine required  : 
Post op headache/back pain
   Pre 
OP 
10 min post 
spinal 
anaesthesia 
   Post OP 
   
0 3 5
1
0
1
5
2
0
2
5
3
0
3
5
4
0
4
5
0 3 5
1
0
1
5
2
0
2
5
3
0
3
5
4
0
4
5
0 3 5
1
0
1
5
2
0
2
5
3
0
3
5
4
0
4
5
P
r
e
 
O
p
1
0
 
m
i
n
 
a
f
t
e
r
 
s
p
i
n
a
l
 
a
n
a
e
s
t
h
e
s
i
a
P
o
s
t
 
O
p
1 Meenakshi sundaram 44 M I BB 119 Appendicectomy 4 5 345 298 251 68 88 96 74 61 78 99 65 94 78 81 67 98 66 99 66 94 81 98 76 79 97 100 98 98 99 99 97 98 97 98 100 97 1 3 2
2 Nallamuthu        60 M I BB 115 Hernioplasty 4 3 303 267 279 79 63 73 95 49 68 64 92 87 96 70 98 89 55 81 76 67 73 74 64 72 69 97 100 99 100 97 100 98 97 97 97 99 1 2 2
Bradycardia,Hy
potension
3 Seetha            55 F I BB 92 Hernioplasty 4 3 327 323 250 60 89 85 64 93 92 75 93 76 74 67 76 65 90 95 77 60 95 68 90 98 75 100 99 97 100 97 100 97 98 100 99 99 1 2 3 Shivering
4 Ganesh            29 M I BB 103 Appendicectomy 3 4 338 334 277 76 65 93 93 62 94 95 81 86 78 60 70 63 66 82 89 77 70 70 86 77 71 98 100 98 98 98 99 97 98 100 100 99 2 3 2
5 Ponnusamy         57 M I BB 98 Hernioplasty 3 4 350 359 257 91 99 68 88 81 82 76 99 65 70 81 79 66 83 84 94 69 90 75 85 65 75 98 98 97 100 97 97 100 99 100 100 99 2 3 3 vomiting
6 Jeyaraman         55 M I BB 99 Hernioplasty 4 5 319 354 261 84 61 65 73 90 89 63 92 93 98 78 93 90 100 96 69 84 86 76 68 76 80 98 100 98 100 100 97 99 100 100 97 100 2 3 3
7 Rani              40 F I BB 101 Appendicectomy 3 3 358 291 252 91 94 74 87 92 45 92 76 89 75 100 89 68 97 63 70 68 72 83 73 62 100 98 99 97 98 99 99 97 99 99 99 100 2 3 2 Bradycardia,
8 Loganathan        34 M I BB 105 Hernioplasty 3 3 355 275 298 77 75 94 98 80 62 97 94 74 60 77 70 99 67 90 73 94 87 60 95 66 72 97 98 100 98 97 97 99 100 99 99 99 2 3 3
9 Neelakandan       45 M I BB 117 Hernioplasty 4 3 357 283 299 95 63 92 71 62 61 94 76 96 61 98 74 88 98 59 67 97 72 74 77 99 71 97 99 100 99 98 97 97 99 99 97 97 2 3 3 Hypotension
10 Mohan             39 M I BB 110 Appendicectomy 3 5 360 360 292 74 98 63 80 91 86 62 74 66 69 89 89 67 96 75 68 64 78 77 60 81 79 97 98 99 98 97 100 98 97 100 99 100 1 2 2
11 Mani              36 F I BB 105 Hernioplasty 4 4 335 254 287 73 96 65 67 74 93 91 76 77 69 68 84 98 74 78 73 80 69 65 71 76 93 97 98 97 98 97 98 98 99 100 100 97 2 3 2
12 Tamilvannan       29 M II BB 120 Hernioplasty 3 4 352 360 267 79 88 81 44 61 81 86 96 71 68 83 86 87 65 94 92 77 65 68 97 91 93 97 97 97 100 99 98 99 99 97 97 100 1 3 2 Bradycardia,
13 Knadapalam        31 M I BB 92 Hernioplasty 4 4 346 341 275 95 78 68 63 76 80 72 61 73 68 76 81 78 94 82 63 80 80 63 73 69 69 100 97 99 100 97 98 98 100 97 98 98 1 2 3
14 Moorthy           44 M II BB 91 Appendicectomy 3 5 309 291 282 75 68 95 87 97 87 95 76 95 68 67 80 95 60 60 99 81 74 95 78 89 78 100 100 97 99 100 100 99 98 99 97 97 2 3 2
15 Vijaya            60 F I BB 113 Hernioplasty 3 3 337 262 269 94 76 84 93 93 62 72 69 65 97 94 93 69 77 75 95 99 79 73 96 70 75 100 100 98 99 100 99 99 97 100 99 98 2 3 3 Vomiting
16 Srinivasan        38 M I BB 115 Hernioplasty 3 4 303 300 297 61 74 80 92 68 78 72 62 80 78 78 99 76 60 97 64 95 67 95 90 78 94 97 97 99 98 99 98 100 99 98 97 98 1 2 2
17 Ponnusamy         43 M I BB 100 Appendicectomy 3 3 357 243 260 69 92 82 74 100 86 69 64 66 70 78 65 61 95 62 62 77 96 64 84 78 70 97 100 98 97 99 98 97 98 100 97 98 1 2 3
18 Ramamoorthy       45 M II BB 96 Hernioplasty 4 4 310 331 262 70 97 60 95 46 83 78 98 62 87 60 61 80 53 77 75 92 95 65 60 62 66 99 99 99 97 97 97 97 99 97 99 100 2 2 3
Bradycardia,Hy
potension
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19 Sivakami          31 F II BB 107 Appendicectomy 3 3 329 288 251 82 67 98 72 85 97 98 92 99 99 87 86 62 67 68 66 63 82 93 63 81 97 97 97 97 99 100 98 100 100 100 100 100 2 3 2 Vomiting
20 Chandran          39 M II BB 93 Hernioplasty 4 5 338 308 275 95 76 72 78 74 98 66 98 66 80 82 96 83 83 77 66 62 85 73 68 77 60 99 98 98 98 99 98 99 100 98 100 98 2 2 2 Shivering
21 Thirunavukarasu   58 M I BB 96 Appendicectomy 3 4 317 332 275 60 98 94 80 98 80 85 94 85 89 63 75 92 67 54 74 92 66 70 92 74 67 100 99 100 100 98 97 100 99 98 99 99 1 3 2 Hypotension
22 Ravi              21 M II BB 117 Hernioplasty 3 3 353 317 267 61 93 71 100 98 65 84 80 86 71 95 93 99 60 56 89 92 73 74 70 69 87 100 98 99 99 99 97 99 98 97 97 98 2 2 3 Hypotension
23 Asokan            24 M II BB 97 Hernioplasty 4 4 324 257 290 94 77 90 86 90 98 81 68 91 97 91 91 92 60 57 80 93 84 72 96 94 77 97 97 98 99 98 98 98 100 98 98 100 2 3 2 Hypotension
24 Govindaraj        51 M I BB 92 Hernioplasty 4 5 304 274 259 92 95 71 70 78 86 68 74 92 84 89 84 94 66 79 88 86 100 89 78 85 70 100 100 99 97 97 98 98 99 97 97 97 1 2 2 Vomiting
25 Rajendran         55 M I BB 102 Hernioplasty 4 5 314 266 281 88 98 78 44 84 66 81 89 76 85 79 84 82 78 91 66 61 68 64 98 100 81 97 97 100 100 100 97 98 100 98 98 98 2 2 3 Bradycardia,
26 Kannan            55 M II BB 109 Appendicectomy 3 4 324 266 293 61 99 99 79 71 60 67 85 87 67 67 63 64 62 81 59 93 100 66 98 71 83 100 98 99 98 98 98 97 99 100 100 100 1 2 3 Hypotension
27 Vadivel           41 M II BB 93 Hernioplasty 3 3 314 322 282 86 73 64 73 66 82 82 95 95 94 61 75 80 73 99 55 96 61 67 99 65 65 97 97 100 98 99 100 97 100 97 100 100 2 3 3 Hypotension
28 Ravichandran      19 M II BB 119 Hernioplasty 3 3 343 266 266 63 69 99 72 70 84 67 77 67 85 66 80 61 90 86 67 69 87 63 85 76 66 100 100 97 98 97 100 97 97 97 99 99 1 3 3
Nausea, 
Vomiting
29 Rajendran         39 M I BB 95 Hernioplasty 4 4 331 281 256 87 67 96 86 94 71 94 65 65 76 72 80 74 81 74 91 73 74 90 96 65 99 97 99 99 97 99 99 100 100 98 100 97 2 2 3 Shivering
30 Appadurai         19 M I BB 103 Hernioplasty 4 3 308 256 258 88 68 69 73 48 83 68 67 73 100 60 76 97 86 87 79 100 79 71 98 83 74 100 99 97 100 100 100 99 97 100 99 99 1 3 2 Bradycardia,
31 Rajesh            25 M I BD 114 Hernioplasty 2 3 518 458 391 99 73 79 78 90 94 83 74 100 70 100 88 69 61 99 88 68 84 71 81 64 94 99 100 100 99 97 99 99 97 98 98 100 3 3 3
32 Gurumoorthy       51 M I BD 111 Appendicectomy 3 4 501 454 406 79 63 79 73 67 97 80 96 86 94 70 65 93 100 99 80 94 98 74 82 61 85 97 97 98 98 100 99 99 99 98 99 99 3 3 3
33 Jenitha           25 F I BD 110 Hernioplasty 3 5 520 413 409 74 84 75 92 94 86 93 86 83 100 86 77 70 67 94 62 87 83 72 96 65 92 99 98 99 97 100 100 100 100 100 99 97 2 3 3
34 Senthil kumar     40 M I BD 90 Hernioplasty 2 4 490 435 391 77 72 100 82 61 93 64 98 65 72 92 81 78 93 64 85 78 62 97 68 73 79 100 100 98 99 98 100 98 98 98 98 98 2 2 3
35 Selvaraj          52 M I BD 105 Hernioplasty 3 3 480 414 394 71 89 89 72 78 78 68 96 88 83 79 90 72 90 95 87 74 66 85 72 87 96 99 99 100 97 99 97 99 100 97 97 98 2 2 2
36 Rajeshwari        45 F I BD 111 Appendicectomy 3 4 488 426 392 73 71 60 99 89 84 89 84 99 83 71 94 80 70 77 96 69 79 97 81 60 66 98 100 98 98 97 100 97 98 100 99 98 2 3 2
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37 Thangam           37 F I BD 116 Hernioplasty 2 4 507 429 394 60 67 90 87 88 81 96 73 79 61 93 78 68 96 75 63 76 73 92 60 72 74 99 97 97 100 100 99 98 98 97 97 98 2 3 2
38 Narayanan         60 M I BD 120 Hernioplasty 3 5 511 431 409 70 67 75 74 61 82 60 65 63 74 61 86 91 73 92 97 98 94 80 87 70 88 98 99 97 97 98 98 97 98 98 98 97 3 3 3
39 Rajeshkanna       24 M I BD 118 Appendicectomy 2 3 516 429 404 65 81 93 82 77 80 72 67 69 79 84 70 85 95 90 84 92 61 69 71 77 66 99 97 97 100 100 99 97 98 97 100 100 2 3 2
40 Natarajan         60 M I BD 115 ` 3 4 486 431 395 83 69 64 81 84 67 68 95 89 93 77 77 91 84 60 71 66 88 84 99 64 86 100 100 100 99 98 97 98 100 99 100 97 2 3 3
41 Subramaniyan      37 M I BD 115 Appendicectomy 2 4 505 435 401 72 94 96 61 96 94 74 86 73 80 62 96 97 64 74 90 69 69 62 84 83 61 100 100 100 99 100 97 97 100 98 97 98 3 3 3
42 Natrajan          49 M II BD 101 Hernioplasty 3 4 487 414 405 90 71 93 92 66 74 84 90 89 71 83 95 94 91 81 66 66 74 74 74 75 61 98 99 98 98 100 99 98 100 98 97 98 2 3 2
43 Aruvambal         45 F I BD 104 Hernioplasty 3 4 502 426 391 87 75 81 91 84 70 88 65 87 78 68 67 69 65 89 82 62 82 64 98 65 72 98 100 98 98 97 98 97 100 97 99 98 3 3 2
44 Robinson          35 M II BD 98 Appendicectomy 3 3 518 429 392 68 68 77 85 97 74 84 89 86 100 62 62 76 80 98 64 60 87 64 69 100 66 100 98 97 100 97 99 98 98 98 100 98 3 3 3
45 Arokiadoss        46 M I BD 99 Hernioplasty 2 4 486 431 409 78 63 93 66 73 67 73 65 74 78 75 94 93 75 77 78 87 86 65 92 68 72 99 99 99 97 98 98 99 99 100 97 97 3 3 2
46 Gandhimathi       55 F I BD 96 Hernioplasty 2 3 509 426 403 83 75 69 65 70 45 60 89 82 74 62 71 96 64 78 92 94 72 75 96 93 60 99 98 99 99 98 100 97 100 97 98 98 2 2 3 Bradycardia
47 Sekar             45 M I BD 120 Appendicectomy 2 4 507 429 392 67 61 63 89 77 75 67 65 76 61 67 60 89 98 87 74 94 88 64 62 86 87 99 97 97 100 100 98 97 98 99 100 99 2 3 3
48 Kannadasan        18 M II BD 95 Hernioplasty 3 5 484 431 395 79 82 68 85 82 62 96 77 64 93 71 80 60 77 89 64 69 92 70 77 86 62 99 97 97 98 100 100 99 98 97 97 99 2 3 2
49 Bagyam            60 F II BD 111 Hernioplasty 3 3 502 430 391 70 75 85 63 94 90 74 96 60 82 69 89 71 61 65 69 99 65 84 89 69 90 98 97 98 98 98 100 100 100 97 98 100 3 2 3
50 Muthukumar        38 M II BD 90 Appendicectomy 3 3 490 456 395 90 68 74 94 68 94 66 69 85 97 82 71 73 72 93 91 84 95 71 100 91 65 100 98 99 100 100 99 97 100 98 99 98 3 2 2
51 Sivashankar       41 M I BD 112 Hernioplasty 3 5 500 460 404 67 69 78 63 49 97 69 61 84 87 94 87 84 100 73 62 96 73 80 82 88 73 97 99 97 99 99 97 100 97 97 97 99 2 2 3 Bradycardia
52 Gunasundari       24 F II BD 113 Hernioplasty 2 4 511 436 398 85 69 87 92 80 97 60 92 64 62 72 78 88 71 63 62 61 82 71 97 76 84 99 98 100 98 97 97 98 100 98 98 99 3 3 2
53 Ravi              58 M II BD 115 Appendicectomy 2 5 500 435 396 79 73 90 98 81 100 84 73 72 76 66 66 86 96 96 67 83 78 68 100 62 72 98 97 99 98 99 99 98 100 97 98 100 3 3 2
54 Anbalagan         45 M I BD 114 Hernioplasty 2 5 509 414 404 86 68 97 95 75 96 90 69 96 63 76 88 71 79 95 88 61 91 92 80 89 84 100 97 97 100 97 98 97 97 99 97 98 2 2 2
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55 Mohamed raffiq    31 M I BD 108 Appendicectomy 3 5 515 426 389 77 92 65 67 60 83 65 68 73 83 60 84 70 75 65 89 82 61 77 85 79 88 100 99 98 100 99 99 99 100 98 99 99 3 3 3
56 Rajangam          23 M II BD 100 Hernioplasty 3 5 511 426 398 83 93 97 63 74 96 95 87 68 79 87 80 96 92 99 64 72 84 95 68 79 76 99 97 100 98 97 100 99 98 100 98 99 3 2 2
57 Sundaraj          24 M II BD 91 Hernioplasty 2 5 488 429 392 92 85 84 73 90 77 97 69 71 78 99 75 77 96 75 98 93 76 86 88 66 60 100 97 100 97 100 99 99 100 98 99 98 2 2 2
58 Govindaraj        49 M II BD 107 Appendicectomy 3 5 519 431 396 75 67 69 86 63 62 92 99 85 95 62 79 87 64 69 87 89 92 61 90 77 78 99 97 100 98 99 100 99 97 98 100 98 3 3 2
59 Veerapandi        22 M I BD 110 Hernioplasty 3 5 513 430 398 78 72 89 71 83 98 72 88 69 91 88 81 81 63 95 69 98 73 98 90 93 90 99 97 97 100 98 100 98 98 97 99 97 2 2 2
60 Marimuthu         42 M I BD 91 Hernioplasty 2 4 491 456 409 66 72 73 91 83 79 94 65 66 85 73 96 72 98 90 100 65 80 67 86 75 100 98 98 100 98 100 100 97 99 99 100 98 3 2 2
